NZ718992B2 - Prostamide-containing intraocular implants and methods of use thereof - Google Patents
Prostamide-containing intraocular implants and methods of use thereof Download PDFInfo
- Publication number
- NZ718992B2 NZ718992B2 NZ718992A NZ71899214A NZ718992B2 NZ 718992 B2 NZ718992 B2 NZ 718992B2 NZ 718992 A NZ718992 A NZ 718992A NZ 71899214 A NZ71899214 A NZ 71899214A NZ 718992 B2 NZ718992 B2 NZ 718992B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- implant
- eye
- lactide
- weight
- intraocular
- Prior art date
Links
- 239000007943 implant Substances 0.000 title claims abstract description 501
- AQOKCDNYWBIDND-FTOWTWDKSA-N Bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 title claims abstract description 194
- 229960002470 bimatoprost Drugs 0.000 title claims abstract description 194
- 210000001508 Eye Anatomy 0.000 claims abstract description 222
- 229920000642 polymer Polymers 0.000 claims abstract description 94
- 210000002159 Anterior Chamber Anatomy 0.000 claims abstract description 89
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 80
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 55
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 55
- 230000001603 reducing Effects 0.000 claims abstract description 50
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims description 82
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 57
- 238000006065 biodegradation reaction Methods 0.000 claims description 49
- 208000010412 Glaucoma Diseases 0.000 claims description 48
- 239000011159 matrix material Substances 0.000 claims description 40
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 38
- 150000002148 esters Chemical class 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 238000001125 extrusion Methods 0.000 claims description 27
- 210000000871 Endothelium, Corneal Anatomy 0.000 claims description 26
- 229940050929 POLYETHYLENE GLYCOL 3350 Drugs 0.000 claims description 23
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 23
- 230000004406 elevated intraocular pressure Effects 0.000 claims description 20
- 210000004127 Vitreous Body Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- JJTUDXZGHPGLLC-UHFFFAOYSA-N dilactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 16
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 5
- 238000009474 hot melt extrusion Methods 0.000 claims description 4
- 125000002015 acyclic group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000005842 heteroatoms Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 claims description 2
- 125000004434 sulfur atoms Chemical group 0.000 claims description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract description 17
- 230000002459 sustained Effects 0.000 abstract description 11
- -1 bimatoprost Chemical compound 0.000 abstract description 6
- 229920000747 poly(lactic acid) polymer Polymers 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 51
- 238000009472 formulation Methods 0.000 description 45
- 229940079593 drugs Drugs 0.000 description 38
- 239000002202 Polyethylene glycol Substances 0.000 description 22
- 229920001223 polyethylene glycol Polymers 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 210000000554 Iris Anatomy 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 16
- 210000001742 Aqueous Humor Anatomy 0.000 description 13
- 241000282472 Canis lupus familiaris Species 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 13
- 230000004059 degradation Effects 0.000 description 13
- 238000006731 degradation reaction Methods 0.000 description 13
- 206010030348 Open angle glaucoma Diseases 0.000 description 12
- 210000001519 tissues Anatomy 0.000 description 12
- 206010011033 Corneal oedema Diseases 0.000 description 11
- 201000002862 angle-closure glaucoma Diseases 0.000 description 11
- 201000004778 corneal edema Diseases 0.000 description 11
- 210000000399 corneal endothelial cell Anatomy 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 201000004569 blindness Diseases 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 210000001328 Optic Nerve Anatomy 0.000 description 9
- 238000002513 implantation Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 230000004380 optic nerve Effects 0.000 description 9
- 150000003180 prostaglandins Chemical class 0.000 description 9
- 230000004393 visual impairment Effects 0.000 description 9
- 210000004087 Cornea Anatomy 0.000 description 8
- 210000000695 Crystalline Lens Anatomy 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 206010067013 Normal tension glaucoma Diseases 0.000 description 8
- 201000002978 low tension glaucoma Diseases 0.000 description 8
- 230000002522 swelling Effects 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 7
- 230000001965 increased Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 210000001747 Pupil Anatomy 0.000 description 6
- 230000002354 daily Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000000699 topical Effects 0.000 description 6
- 229940012356 Eye Drops Drugs 0.000 description 5
- 206010068960 Narrow anterior chamber angle Diseases 0.000 description 5
- 210000001585 Trabecular Meshwork Anatomy 0.000 description 5
- 239000002220 antihypertensive agent Substances 0.000 description 5
- 210000004027 cells Anatomy 0.000 description 5
- 230000001886 ciliary Effects 0.000 description 5
- 230000003628 erosive Effects 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 230000001631 hypertensive Effects 0.000 description 5
- 201000006366 primary open angle glaucoma Diseases 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 231100000730 tolerability Toxicity 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 229940112534 Lumigan Drugs 0.000 description 4
- 210000003205 Muscles Anatomy 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000011068 load Methods 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 210000004240 Ciliary Body Anatomy 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010052639 Nerve injury Diseases 0.000 description 3
- 210000001525 Retina Anatomy 0.000 description 3
- 210000003786 Sclera Anatomy 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 201000001326 acute closed-angle glaucoma Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000001186 cumulative Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 230000003442 weekly Effects 0.000 description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N Anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 2
- 206010053781 Anterior chamber cell Diseases 0.000 description 2
- 206010052127 Anterior chamber flare Diseases 0.000 description 2
- 229940072107 Ascorbate Drugs 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 210000003161 Choroid Anatomy 0.000 description 2
- 210000000795 Conjunctiva Anatomy 0.000 description 2
- 206010011024 Corneal injury Diseases 0.000 description 2
- 210000003038 Endothelium Anatomy 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- OAIJSZIZWZSQBC-LWRKPGOESA-N Lycopene Natural products CC(C)=CCC\C(C)=C/C=C/C(/C)=C\C=C\C(\C)=C/C=C/C=C(/C)\C=C\C=C(\C)/C=C/C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-LWRKPGOESA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010030047 Ocular injury Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102100015381 PTGS2 Human genes 0.000 description 2
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 2
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 2
- 102100007116 SLCO2A1 Human genes 0.000 description 2
- 101710041298 SLCO2A1 Proteins 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 230000003276 anti-hypertensive Effects 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000005682 chronic closed-angle glaucoma Diseases 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004049 embossing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001077 hypotensive Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 230000002250 progressing Effects 0.000 description 2
- 230000002207 retinal Effects 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002174 soft lithography Methods 0.000 description 2
- 238000000807 solvent casting Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N trans-Retinyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N (1R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(1R,4R)-4-hydroxy-2,6,6-trimethylcyclohex-2-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-3-en-1-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N (1R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-3,5,5-trimethylcyclohex-3-en-1-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MQZIGYBFDRPAKN-QISQUURKSA-N 6-hydroxy-3-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-(4-hydroxy-2,6,6-trimethyl-3-oxocyclohexen-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC=1C(=O)C(O)CC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)C(O)CC1(C)C MQZIGYBFDRPAKN-QISQUURKSA-N 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 229940030600 ANTIHYPERTENSIVES Drugs 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940102480 Bilberry extract Drugs 0.000 description 1
- 101700050822 CKX1 Proteins 0.000 description 1
- 229940044199 Carnosine Drugs 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 229940069275 Cosopt Drugs 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N Cryptoxanthol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 229960002433 Cysteine Drugs 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 241001212789 Dynamis Species 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000007290 Eye Hemorrhage Diseases 0.000 description 1
- 210000000744 Eyelids Anatomy 0.000 description 1
- 229940068052 Ginkgo biloba extract Drugs 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067684 Iris bombe Diseases 0.000 description 1
- 206010023332 Keratitis Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- RITKHVBHSGLULN-WHFBIAKZSA-N L-γ-glutamyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(O)=O RITKHVBHSGLULN-WHFBIAKZSA-N 0.000 description 1
- 229940078795 Lactoferrin Drugs 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 229960005375 Lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-NRHWGSPPSA-N Lutein Natural products O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](O)CC=2C)\C)/C)\C)/C)C(C)(C)C1 KBPHJBAIARWVSC-NRHWGSPPSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229940054534 Ophthalmic Solution Drugs 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710040931 PTGS1 Proteins 0.000 description 1
- 102100006335 PTGS1 Human genes 0.000 description 1
- 101710040930 PTGS2 Proteins 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N Phenethyl alcohol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- 229940096826 Phenylmercuric Acetate Drugs 0.000 description 1
- VUXSPDNLYQTOSY-UHFFFAOYSA-N Phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
- 229960002553 Phenylmercuric nitrate Drugs 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M Phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 206010035015 Pigmentary glaucoma Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010037520 Pupillary block Diseases 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 208000004644 Retinal Vein Occlusion Diseases 0.000 description 1
- 229940100996 SODIUM BISULFATE Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide Dismutase Proteins 0.000 description 1
- 229960003080 Taurine Drugs 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N Tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229960004441 Tyrosine Drugs 0.000 description 1
- 229940116269 Uric Acid Drugs 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-PQJNXSRMSA-N Zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-PQJNXSRMSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940087168 alpha Tocopherol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 235000019209 bilberry extract Nutrition 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine zwitterion Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 229930016253 catechin Natural products 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 108010068906 gamma-glutamylcysteine Proteins 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011874 heated mixture Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000007925 in vitro drug release testing Methods 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000266 injurious Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 238000011031 large scale production Methods 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N nitrooxy(phenyl)mercury Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960000247 phenylmercuric borate Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000009725 powder blending Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 200000000025 progressive disease Diseases 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229950004578 vitamin A palmitate Drugs 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Abstract
Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described. ide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
Description
PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANTS AND METHODS OF USE
THEREOF
By Alazar N. Ghebremeskel and Michael R. Robinson
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application No. 61/898,241
filed on October 31, 2013, the entire content of which is incorporated herein by reference.
BACKGROUND
Described herein are biodegradable intraocular implants that provide for the extended
release of bimatoprost in an amount that is effective for treating an ocular condition, particularly
glaucoma and ocular hypertension, and conditions associated with glaucoma such as elevated
intraocular pressure. The implants, which may be produced by an extrusion process, are sized
and configured for placement in the anterior chamber of the eye where the implant can deliver
the prostamide directly to the tissues regulating the production and outflow of aqueous humor.
Importantly, the intraocular implants described here are designed not only to provide a patient
with intraocular pressure-lowering levels of bimatoprost for a sustained period lasting for 2
months or more but are also sized to fit within the anterior chamber angle (also called the
iridocorneal angle) of the eye without injuring the corneal endothelium and without obstructing
vision. Though developed for the delivery of bimatoprost, implants described herein may be
useful for the sustained delivery of other prostamides as well. Methods for making and using
these implants to treat an ocular condition are described.
Prostamides are potent ocular hypotensive agents useful in the treatment of a number
of various ocular hypertensive conditions such as glaucoma, elevated intraocular pressure, and
other ocular hypertensive episodes, including post-surgical and post-laser ocular hypertensive
episodes (1, 4). They belong to an ever-expanding family of prostaglandin F C-1 amides (1-5).
The biosynthesis and pharmacology of prostamides has been extensively described (1-3, 9). For
example, naturally occurring prostamides, such as prostamide F , are biosynthesized from
anandamide by a pathway exclusively involving COX-2. COX-1 is not involved (1, 2, 15).
Docket No. 19235 (AP) PATENT
One prostamide that has found wide-spread use in ocular therapy is bimatoprost. Like
other prostamides, bimatoprost exhibits no meaningful interaction with prostaglandin (PG)
sensitive receptors (3, 10). Nevertheless, bimatoprost is a potent ocular anti-hypertensive agent
and is highly effective for reducing elevated intraocular pressure in patients with open angle
glaucoma or ocular hypertension (1, 6-8). Bimatoprost is typically prescribed for use by patients
in the form of an ophthalmic solution known by the tradename LUMIGAN®. In the usual course
of therapy, Patients apply one drop of LUMIGAN® solution once daily to the surface of the
affected eye(s) to reduce elevated intraocular pressure. Bimatoprost is believed to decrease
intraocular pressure (IOP) by increasing aqueous humor outflow through the uveoscleral
pathway (1, 3).
While highly effective for reducing intraocular pressure, the regular daily instillation
of bimatoprost eye drops, nevertheless, requires daily management by the patient. It would be
advantageous for some patients to have access to implantable drug delivery systems, such as
intraocular implants, that are capable of delivering a therapeutically effective amount of
bimatoprost to the eye at a consistent rate for an extended period to thereby reduce intraocular
pressure in a hypertensive eye continuously for longer durations such as 2 months or more. A
biodegradable intraocular implant, sized and configured for safe comfortable placement in the
eye, and properly formulated to deliver a therapeutic amount of bimatoprost to tissues in the eye
would effectively eliminate the need for patient compliance, since a patient would no longer
need to apply daily eye drops, and by maintaining intraocular pressure at or below the levels
typically obtained by topical application continuously for an extended period (such as 2 months
Docket No. 19235 (AP) PATENT
or more), an intraocular implant may improve glaucoma therapy and lead to better therapeutic
outcomes in some patients. Intraocular implants that include a prostamide component and a
biodegradable polymer for the extended release of a prostamide such as bimatoprost, to treat an
ocular condition such as glaucoma have been described (Ref. 4, for example).
Glaucoma is generally a progressive disease of the eye characterized by progressive
optic neuropathy with associated visual field loss. Glaucoma may be further associated with
increased intraocular pressure. On the basis of its etiology, glaucoma has been classified as
primary or secondary. Primary glaucoma in adults may be either open-angle glaucoma or acute
or chronic angle-closure glaucoma. Secondary glaucoma results from pre-existing ocular
diseases such as uveitis, intraocular tumor or an enlarged cataract.
The underlying causes of primary glaucoma are not yet known. Risk factors include
high or elevated intraocular pressure, advanced age, and family history. Increased or elevated
intraocular pressure is due to the obstruction of aqueous humor outflow. In primary open-angle
glaucoma, the anterior chamber and its anatomic structures appear normal, but drainage of the
aqueous humor is impeded. In acute or chronic angle-closure glaucoma, the anterior chamber is
shallow, the filtration angle is narrowed, and the iris may obstruct the trabecular meshwork at the
entrance of the canal of Schlemm. Dilation of the pupil may push the root of the iris forward
against the angle, and may produce pupillary block and thus precipitate an acute attack. Eyes
with narrow anterior chamber angles are predisposed to acute angle-closure glaucoma attacks of
various degrees of severity.
Secondary glaucoma is caused by any interference with the flow of aqueous humor
from the posterior chamber into the anterior chamber and subsequently, into the canal of
Schlemm. Inflammatory disease of the anterior segment may prevent aqueous escape by causing
complete posterior synechia in iris bombe and may obstruct movement of aqueous humor
through the pupil leading to elevated intraocular pressure. Other common causes are intraocular
tumors, enlarged cataracts, central retinal vein occlusion, trauma to the eye, operative procedures
and intraocular hemorrhage. Considering all types together, glaucoma occurs in about 2% of all
persons over the age of 40 and may be asymptomatic for years before progressing to noticeable
peripheral visual loss followed by central vision loss.
Docket No. 19235 (AP) PATENT
Glaucoma can be considered to be potentially both an anterior and posterior ocular
condition because a clinical goal of glaucoma treatment can be not only to reduce elevated
intraocular pressure because of obstructed aqueous humor outflow from the anterior chamber,
but to also prevent the loss of or reduce the occurrence of loss of vision due to damage to or loss
of retinal cells or optic nerve cells (i.e., ganglion cells) in the posterior of the eye (i.e.
neuroprotection). Clinical trials have shown that reducing IOP can help retard the progression of
glaucoma and consistent IOP reduction is associated with reduced risks of developing and
progressing optic nerve damage (11-13).
Patient non-adherence to topical therapy is one of the major challenges to preventing
vision loss due to glaucoma. Patients that take no medication are at the highest risk of vision loss
from glaucoma; however, patients that intermittently take their medications are also at risk since
IOP fluctuation has also been identified as possible risk factor for progression in some patients
(14).
Accordingly, sustained-release drug delivery systems, such as biodegradable
intraocular implants, that can continuously deliver a therapeutically effective amount of an anti-
hypertensive drug such as bimatoprost directly into the anterior chamber of the eye may help
reduce patient dependence on topical ocular anti-hypertensives or other anti-glaucoma
medications to control intraocular pressure and manage symptoms associated with glaucoma.
The present invention provides for such drug delivery systems and offers additional
improvements relative to some existing biodegradable intraocular implants. We have discovered
a biodegradable implant formulation that swells less and biodegrades faster than some
comparable intraocular implants, yet releases a therapeutically effective amount of bimatoprost
at a nearly linear or constant rate for a sustained period (e.g., about 60 days), thereby providing
patients with long-lasting relief from ocular hypertension and possibly protecting patients from
some of the adverse effects caused by high or elevated intraocular pressure.
Such attributes are particularly valuable for implants placed in the anterior chamber
of the eye (the fluid-filled space inside the eye between the iris and the innermost corneal
surface, the corneal endothelium). Because most anterior chamber implants are more dense than
aqueous humor, they tend to settle inferiorly into the angle of the anterior chamber (the junction
between the front surface of the iris and the back surface of the cornea; also called the
Docket No. 19235 (AP) PATENT
iridocorneal angle) after injection into the anterior chamber, where they may contact and
possibly injure the corneal endothelium. Small, low-swell, rapidly degraded implants (i.e.
implants that swell to less than 3 times (<3X) the initial size when placed in the anterior
chamber), such as the ones we describe here, may reduce the risk of a patient developing corneal
edema due to mechanical irritation of the corneal endothelium. In contrast, implants that swell
greater than 3 fold (>3X) the initial size when placed in the anterior chamber have a higher risk
of corneal endothelial cell touch and formation of corneal edema. Corneal edema can lead to
cloudiness of normally transparent cornea and may result in vision loss if it extends to the central
cornea. Furthermore, a small, low-swell implant that stays at a maximum swell for a shorter
period before decreasing in size may enable physicians to safely administer the implant to a
larger population of patients, including those with small or narrow anterior chamber angles.
Rapid biodegradation of an implant after its drug load has been delivered means that a patient
can receive one or more additional implants as needed as part of their continued therapy without
having to worry about residual implants compromising their vision or comfort. It is an object of
the present invention to go some way towards overcoming these issues and/or to at least provide
the public with a useful choice.
All such considerations, including the optimal size of the implant (e.g., length,
diameter or width, and total mass) have been taken into account here in the development of the
presently described implants.
References cited:
1. Woodward et al. (2001) “The pharmacology of Bimatoprost (Lumigan®)” Survey of
Ophthalmology Vol. 45, Supplement 4, pp. S337-S345.
2. Woodward et al. (2008) “Prostamides (prostaglandin ethanolamides) and their
pharmacology”British J. Pharmacology 153:410-419.
3. Woodward et al. (2004) “Bimatoprost: A novel antiglaucoma agent” Cardiovascular Drug
Reviews 22(2):103–120.
4. U.S. Patent 7,799,336, which is herein incorporated by reference.
. U.S. Patent 6,395,787, which is herein incorporated by reference.
Docket No. 19235 (AP) PATENT
6. Coleman et al. (2003) “A 3-Month Randomized Controlled Trial of Bimatoprost
(LUMIGAN®) versus Combined Timolol/Dorzolamide (Cosopt®) in Patients with Glaucoma or
Ocular Hypertension” Ophthalmology 110(12): 2362-8.
7. Laibovitz et al. (2001) “Comparison of the ocular hypotensive lipid AGN 192024 with
timolol. Dosing, efficacy and safety evaluation of a novel compound for glaucoma management”
Arch Ophthalmol 119:994–1000.
8. Cantor (2008) “An update on bimatoprost in glaucoma therapy” Expert Opin. Pharmacother.
3(12):1753-1762.
9. Brubaker et al. (2001) “Effects of AGN 19024, a new ocular hypotensive agent, on aqueous
dynamis” Am. J. Ophthalmol. 131:19-24.
. Schuster et al. (2000) “Synthetic modification of prostaglandin F indicates different
structural determinants for binding to the prostaglandin F receptor versus the prostaglandin
transporter” Mol. Pharmacology 58:1511-1516.
11. Collaborative Normal-tension glaucoma study group. The effectiveness of intraocular
pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmology 1998;
126:498-505.
12. Heijl et al. (2002) “Reduction of intraocular pressure and glaucoma progression: results from
the early manifest glaucoma trial.” Arch. Ophthalmol. 120:1268-1279.
13. Kass et al. (2002) “The ocular hypertension treatment study: a randomized trial determines
that topical ocular hypotensive medication delays or prevents the onset of primary open-angle
glaucoma” Arch. Ophthalmol 120:701-713.
14. Caprioli et al. (2008) “Intraocular pressure fluctuation” Ophthalmology 115(7):1123-1129.
. Yu et al. (1997) “Synthesis of prostaglandin E ethanolamide from anandamide by
cyclooxygenase-2” J. Biol. Chem. 272(34):21181-21186.
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the invention. Unless specifically stated otherwise,
reference to such external documents is not to be construed as an admission that such documents,
or such sources of information, in any jurisdiction, are prior art, or form part of the common
general knowledge in the art.
Docket No. 19235 (AP) PATENT
SUMMARY
[00014a] In a first aspect the present invention provides a biodegradable intraocular implant
for reducing intraocular pressure (IOP) in an eye, the implant comprising a biodegradable
polymer matrix, polyethylene glycol 3350, and a prostamide as the active agent, wherein the
prostamide and polyethylene glycol 3350 are associated with the biodegradable polymer matrix,
which comprises
a) an ester end poly(D,L-lactide) having an inherent viscosity of 0.25-0.35 dl/g,
b) an acid end poly(D,L-lactide) having an inherent viscosity of 0.16-0.24 dl/g, and
c) an ester end poly(D,L-lactide-co-glycolide) having an inherent viscosity of 0.16-
0.24 dl/g and a D,L-lactide to glycolide molar ratio of about 75:25;
wherein the prostamide constitutes 18 to 22% of the implant by weight, the ester end
poly(D,L-lactide) constitutes 18 to 22% of the implant by weight, the acid end poly(D,L-
lactide) constitutes 13.5 to 16.5% of the implant by weight, the ester end poly(D,L-lactide-
co-glycolide) constitutes 36 to 44% of the implant by weight, and wherein the polyethylene
glycol 3350 constitutes 3.5 to 6.5% of the implant by weight, wherein the inherent viscosity
of each of the poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers is determined
for a 0.1% solution of the polymer in chloroform at 25°C.
[00014b] In a second aspect the present invention provides a use of a biodegradable
polymer matrix, polyethylene glycol 3350, and a prostamide as the active agent, in the
manufacture of an intraocular implant for reducing ocular pressure in an eye of a mammal in
need thereof, wherein the intraocular implant is as defined in the first aspect.
[00014c] In a third aspect the present invention provides an apparatus for delivering a
biodegradable intraocular implant into the eye of a patient, the apparatus comprising an
intraocular implant according to the first aspect, an elongate housing and a cannula extending
longitudinally from the housing, the cannula having a proximal end, a distal sharp end, and a
lumen extending therethrough, the lumen having an inner diameter sufficient to receive the
intraocular implant and permit translation of the implant through the lumen and into the eye of
the patient.
Docket No. 19235 (AP) PATENT
[00014d] In a fourth aspect the present invention provides a method for making a
biodegradable intraocular implant according to the first aspect, the method comprising mixing
the prostamide with the poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers and
polyethylene glycol 3350, extruding the mixture to form a filament, followed by cutting the
filament to length suitable for placement in the anterior chamber or vitreous body of an eye to
thereby form an intraocular implant.
The present disclosure describes a bimatoprost-containing biodegradable intraocular
implant for reducing intraocular pressure (IOP) in an eye for at least 2 months. The implant may
be effective for maintaining intraocular pressure in an eye at a reduced level (relative to the
intraocular pressure in the eye before receiving the implant) for 4 months, for 4-6 months, or for
6-12 months or longer than 12 months after placement in the eye. The percent relative reduction
in IOP in an eye after receiving the implant may vary, depending on the size of the implant (and
therefore the drug load) and on the patient, but may be from 10-20%, 20-30%, or 10-50% below
baseline IOP (the intraocular pressure in the eye before receiving the implant) and may, in some
instances, remain at 20-30% below baseline IOP for at least 2 months, 2-3 months, for 4 months
or longer, and in some instances for 6-12 months or longer after implantation of a single implant.
The implant may be placed in an ocular region of an eye of a patient to reduce
intraocular pressure in the eye and thereby to treat ocular hypertension and ocular conditions
associated with elevated intraocular pressure, including glaucoma. The bimatoprost-containing
implant described here is specifically sized and formulated for placement in the anterior chamber
of the eye, but may be adopted for use in the vitreous body of the eye (by intravitreal injection) if
desired and as may be necessary in some patients with a small or narrow anterior chamber angle
or in patients with angle-closure glaucoma. Anterior chamber angle widths may be graded
according to the Shaffer System (Shaffer RN. (1960) “Primary glaucomas. Gonioscopy,
ophthalmoscopy, and perimetry” Trans Am Acad Ophthalmol Otolaryngol. 64:112-127). Shaffer
Grade 1 and Grade 2 angles may be considered narrow. It may be preferable to treat patients that
have either a Shaffer Grade 1 or Grade 2 angle by placing the implant in the vitreous body of the
eye rather than the anterior chamber to reduce the chance of corneal toxicity. Patients with open
Docket No. 19235 (AP) PATENT
angles, such as patients with Shaffer Grade 3 and 4 angles, may be candidates for either an
intracameral implant or an intravitreal implant.
While initially developed for the sustained delivery of bimatoprost, the intraocular
implants, or drug delivery systems, described here may be useful for the delivery of other
prostamides as well, including, but not limited to, the compounds having Formula I, set forth
below.
In general, an intraocular implant in accordance with this disclosure comprises or
consists of bimatoprost as the active agent, a biodegradable polymer matrix, and optionally a
polyethylene glycol. The bimatoprost (or other prostamide) may comprise from 5% to 90% by
weight of the implant, or from 5% to 30% by weight of the implant, or from 18-22% by weight
of the implant, but is preferably 20% by weight of the implant. The biodegradable polymer
matrix will generally comprise a mixture of at least three different biodegradable polymers
independently selected from the group consisting of poly(D,L-lactide) (PLA) polymers and
poly(D,L-lactide-co-glycolide) (PLGA) polymers. For example, the biodegradable polymer
matrix may comprise or consist of first, second, and third biodegradable polymers that differ one
from the other by their repeating unit, inherent viscosity, or end-group, or any combination
thereof. In some instances, the biodegradable polymer matrix according to the present disclosure
may comprise first, second, third, and fourth biodegradable polymers independently selected
from the group consisting of poly(D,L-lactide) (PLA) polymers and poly(D,L-lactide-co-
glycolide) (PLGA) polymers, wherein the first, second, third, and fourth polymers differ one
from the other by their repeating unit, inherent viscosity, or end-group, or any combination
thereof. Depending on the chain terminating agent used during the synthesis of the polymer, a
PLA or PLGA polymer may have a free carboxylic acid end group or alkyl ester end group, and
may be referred to herein as an acid-end or ester-end (or ester-capped) PLA or PLGA polymer,
respectively.
In one embodiment, the biodegradable polymer matrix comprises or consists of first,
second, and third biodegradable polymers, wherein the first biodegradable polymer is an ester-
end poly(D,L-lactide) polymer having an inherent viscosity of 0.25-0.35 dl/g, the second
polymer is an acid-end poly(D,L-lactide) polymer having an inherent viscosity of 0.16-0.24 dl/g,
and the third polymer is a ester-end poly(D,L-lactide-co-glycolide) polymer having a D,L-
Docket No. 19235 (AP) PATENT
lactide:glycolide molar ratio of from 73:27 to 77:23, or about 75:25, and an inherent viscosity of
0.16-0.24 dl/g, where the inherent viscosity of each polymer is determined for a 0.1% w/v
solution of the polymer in chloroform at 25°C.
The prostamide contained by the implant may be uniformly or non-uniformly
distributed throughout the biodegradable polymer matrix. The prostamide may be dispersed
within the biodegradable polymer matrix.
As stated above, the implant may further comprise polyethylene glycol. The
polyethylene glycol contained by the implant may have an average molecular weight of from
3000 to 20,000 g/mol. In one embodiment the implant contains polyethylene glycol 3350 (PEG
3350). The polyethylene glycol will generally be associated with the biodegradable polymer
matrix. For example, the polyethylene glycol may be dispersed within the biodegradable polymer
matrix.
Prostamide-containing implants in accordance with this disclosure are formulated to
i) minimize the swelling of the implant in the liquid filled interior of the eye, ii) hasten implant
degradation following depletion of the drug payload, and iii) to release drug at a substantially
constant (or near linear) rate for an extended period, which may be for 2 months or more
following placement in the eye. Such implants are considered to be well suited for long term
reduction of intraocular pressure in a hypertensive eye. As previously discussed, the implant is
sized to fit in the anterior chamber angle (also called the iridocorneal angle) of the eye
(particularly a human eye) without contacting or without injuring the corneal endothelium.
Minimizing contact between the implant and the corneal endothelium may lower or eliminate the
possibility of the patient developing corneal edema, a condition that can impair vision and
possibly lead to vision loss.
In this regard, one embodiment is a biodegradable intraocular implant for reducing
intraocular pressure or ocular hypertension in a patient, the implant comprising a biodegradable
polymer matrix and a prostamide as the active agent associated with the biodegradable polymer
matrix, the biodegradable polymer matrix comprising or consisting of
a) R203S, which is an ester end poly(D,L-lactide) having an inherent viscosity of
0.25-0.35 dl/g;
Docket No. 19235 (AP) PATENT
b) R202H, which is an acid end poly(D,L-lactide) having an inherent viscosity of
0.16-0.24 dl/g;
c) RG752S, which is an ester end poly(D,L-lactide-co-glycolide) having a D,L-
lactide:glycolide molar ratio of about 75:25 and an inherent viscosity of 0.16-0.24
dl/g; and
d) polyethylene glycol 3350;
wherein the prostamide comprises 20% of the implant by weight, the ester end poly(D,L-lactide)
comprises 20% of the implant by weight, the acid end poly(D,L-lactide) comprises 15% of the
implant by weight, the ester end poly(D,L-lactide-co-glycolide) comprises 40% of the implant by
weight, and wherein the polyethylene glycol (PEG) 3350 comprises 5% of the implant by
weight, wherein the inherent viscosities for each of the poly(D,L-lactide) and poly(D,L-lactide-
co-glycolide) polymers are measured for a 0.1% solution of the polymer in chloroform at 25°C.
In some embodiments, the prostamide is a compound having Formula I. In one
embodiment the prostamide is bimatoprost.
Examples of intraocular implants for use in a method of treating an ocular condition
in accordance with this disclosure include those set forth in Tables 1 and 2, below. For example
an intraocular implant for reducing intraocular pressure and ocular hypertension in a patient may
comprise 20% by weight bimatoprost, 15% by weight R203S, 20% by weight RG858S, 40% by
weight RG752S, and 5% by weight polyethylene glycol 3350. RG858S is an ester end poly(D,L-
lactide-co-glycolide) having an inherent viscosity of 1.3-1.7 dl/g and a D,L-lactide to glycolide
ratio of 83:17 to 87:13, or about 85:15.
Another embodiment is a biodegradable intraocular implant for treating an ocular
condition in an eye of a patient, the implant comprising 18-22% by weight (w/w) bimatoprost,
18-22% by weight R203S, 13.5-16.5% by weight R202H, 36-44% by weight RG752S, and 3.5-
6.5% by weight polyethylene glycol.
An additional embodiment is a biodegradable intraocular implant for treating an
ocular condition in an eye of a patient, the implant comprising 20% by weight (w/w)
bimatoprost, 20% by weight R203S, 15% by weight R202H, 40% by weight RG752S, and 5%
by weight polyethylene glycol.
Docket No. 19235 (AP) PATENT
Another embodiment is a biodegradable intraocular implant for treating an ocular
condition in an eye of a patient, the implant comprising 20% by weight (w/w) bimatoprost, 15%
by weight RG858S, 35% by weight RG752S, 15% by weight RG755S, and 15% by weight
RG502S. RG755S is a poly(D,L-lactide-co-glycolide) having an ester end group, an inherent
viscosity of about 0.50-0.70 dl/g (as measured for a 0.1% solution in chloroform at 25ºC), and a
D,L-lactide:glycolide molar ratio of 73:27 to 77:23, or about 75:25. RG502S is a poly(D,L-
lactide-co-glycolide) having an ester end group, an inherent viscosity of 0.16-0.24 dl/g (as
measured for a 0.1% solution in chloroform at 25ºC), and a D,L-lactide:glycolide ratio of 48:52
to 52:48, or about 50:50.
Another embodiment is a biodegradable intraocular implant for treating an ocular
condition in an eye of a patient, the implant comprising 20% by weight (w/w) bimatoprost, 30%
by weight RG858S, 40% by weight RG752S, 5% by weight RG502, and 5% by weight RG502H.
RG502H is a poly(D,L-lactide-co-glycolide) having an acid end group, an inherent viscosity of
0.16-0.24 dl/g (as measured for a 0.1% solution in chloroform at 25ºC), and a D,L-
lactide:glycolide ratio of about 50:50 (such as for example RG502H).
Another embodiment is a biodegradable intraocular implant comprising 20% by
weight (w/w) bimatoprost, 20% by weight RG752S, 50% by weight RG755S, 5% by weight
RG502, and 5% by weight RG502H.
Another embodiment is a biodegradable intraocular implant comprising 20% by
weight (w/w) bimatoprost, 25% by weight RG752S, 50% by weight RG755S, and 5% by weight
RG502.
Another embodiment is a biodegradable intraocular implant comprising 20% by
weight (w/w) bimatoprost, 30% by weight RG752S, 20% by weight RG502, and 30% by weight
RG858S.
As set forth above, an implant formulation according to this disclosure may contain
bimatoprost or other prostamide. In some embodiments, the prostamide contained by the implant
comprises a compound having the Formula (I)
Docket No. 19235 (AP) PATENT
wherein the dashed bonds represent a single or double bond which can be in the cis or trans
configuration, A is an alkylene or alkenylene radical having from two to six carbon atoms, which
radical may be interrupted by one or more oxide radicals and substituted with one or more
hydroxy, oxo, alkyloxy or alkylcarboxy groups wherein said alkyl radical comprises from one to
six carbon atoms; B is a cycloalkyl radical having from three to seven carbon atoms, or an aryl
radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals having
from four to ten carbon atoms wherein the heteroatom is selected from the group consisting of
nitrogen, oxygen and sulfur atoms; X is –N(R ) wherein R is independently selected from the
group consisting of hydrogen and a lower alkyl radical having from one to six carbon atoms; Z is
1 2 6 6
=O; one of R and R is =O, –OH or a –O(CO)R group, and the other one is –OH or –O(CO)R ,
1 2 6
or R is =O and R is H, wherein R is a saturated or unsaturated acyclic hydrocarbon group
having from 1 to about 20 carbon atoms, or –(CH ) R wherein m is 0 or an integer of from 1 to
, and R is cycloalkyl radical, having from three to seven carbon atoms, or a hydrocarbyl aryl
or heteroaryl radical, as defined above.
In a more specific embodiment the prostamide contained by the implant is
bimatoprost, which has the following chemical structure:
Docket No. 19235 (AP) PATENT
Bimatoprost
CAS Registry No. 1552061
Other examples of prostamides (prostaglandin F2α amides) may include, but are not
limited to, the prostaglandin F amides described in Woodward et al. (2008) “Prostamides
(prostaglandin ethanolamides) and their pharmacology”British J. Pharmacology 153:410-419;
and Schuster et al. (2000) “Synthetic modification of prostaglandin F indicates different
structural determinants for binding to the prostaglandin F receptor versus the prostaglandin
transporter” Molecular Pharmacology 58:1511-1516; and the prostaglandin F amides described
in U.S. Patents 5,688,819 and 5,834,498.
The biodegradable polymer matrix of an implant according to this disclosure may
release a prostamide at a rate to sustain release of a therapeutically effective amount of the
prostamide from the implant for a period of two months from a time in which the implant is
placed in an ocular region of an eye. In some instances, the implant may be effective for
reducing intraocular pressure in an eye for at least 4 months, for 4-6 months or longer, for 6-12
months, or for 12 to 24 months after placement of the implant in an eye. The implant is designed
specifically for placement in the anterior chamber of the eye, but may be suitable for placement
in other ocular regions to treat conditions such as glaucoma and ocular hypertension, or to
generally reduce IOP in an eye. Accordingly, an implant according to this disclosure may, for
example, be placed in the anterior chamber, posterior chamber, or vitreous body of the eye. In
some instances, an implant may be placed in a subconjunctival or subtenon space in the eye.
Docket No. 19235 (AP) PATENT
The polyethylene glycol (PEG) in any of the foregoing embodiments may have an
average molecular mass of from 3,000 to 20,000 g/mol. In preferred embodiments the
polyethylene glycol in the implant is PEG 3350. For example, in one embodiment the present
disclosure describes a biodegradable intraocular implant comprising 20% by weight (w/w)
bimatoprost, 20% by weight R203S, 15% by weight R202H, 40% by weight RG752S, and 5%
by weight polyethylene glycol 3350 (Formulation 2). More generally, the implant can comprise
18-22% by weight (w/w) bimatoprost, 18-22% by weight R203S, 13.5-16.5% by weight R202H,
36-44% by weight RG752S, and 3.5-6.5% by weight polyethylene glycol.
The intraocular implants according to this disclosure may be effective for reducing
intraocular pressure in either a normotensive or hypertensive eye for an extended period. In some
embodiments of the present methods, a patient may have normal tension glaucoma (NTG), with
an intraocular pressure ranging from 11 to 21 mm Hg. Such patients may require even lower eye
pressures to reduce the risk of progressive optic nerve damage and visual field loss, and may
benefit from the intraocular administration of an implant according to this disclosure. Thus, an
implant according to this disclosure may be effective for treating glaucoma in all its forms,
including glaucoma characterized by elevated intraocular pressure, as well as low-tension or
normal-tension glaucoma, since these patients, too, may potentially benefit from a further
reduction in intraocular pressure.
The implant may be effective for reducing intraocular pressure in an eye by 10-20%,
-30%, and possibly by 30-40% or more (with higher drug release rates), relative to the
intraocular pressure (IOP) in the eye before receiving the implant, for 2 months or more, 4
months or more, and potentially 6 months or more, after placement of the implant in the eye.
Such implants may further be effective for reducing the risk of developing, delaying the onset of,
or slowing the progression of glaucomatous damage in an eye of a patient. Glaucomatous
damage in the eye may include damage to the function and/or structure of the optic nerve and
ganglion cell death, which can lead to loss of peripheral visual fields and eventually central
vision loss leading to total blindness. Elevated IOP presents a major risk factor for glaucomatous
field loss.
Accordingly, the presently described implants may be effective for treating a patient
suffering from or diagnosed with an ocular condition selected from glaucoma, open angle
Docket No. 19235 (AP) PATENT
glaucoma, primary open-angle glaucoma, angle-closure glaucoma (sometimes referred to as
closed-angle glaucoma), normal-tension glaucoma, low-tension glaucoma, pseudoexfoliative
glaucoma, developmental glaucoma, or pigmentary glaucoma. One or more of the present
implants may also be useful for reducing and thereby treating ocular hypertension or elevated
intraocular pressure. For example, an implant according to this disclosure may be effective for
reducing intraocular pressure in a patient with open-angle glaucoma, angle-closure glaucoma, or
ocular hypertension. The patient can be a human or non-human mammal. The method will
generally comprise the step of placing the implant in an ocular of the eye affected by the ocular
condition.
Because of their ability to release a therapeutically effective amount of bimatoprost
for an extended period (e.g., 60 days or longer), implants in accordance with this disclosure are
expected to be capable of reducing intraocular pressure in a patient for long periods (e.g., for 4
months or more) without the need for frequent intraocular injections or regular instillation of eye
drops to the ocular surface as may be necessary with topical therapy. Accordingly, in some
forms, the implants described here are used as monotherapy (i.e. used alone to control the IOP
without the use of adjunctive antihypertensive eye drops) to reduce intraocular pressure in a
patient and thereby treat an ocular condition as described herein. Nevertheless, an implant in
accordance with this disclosure can, if desired, be used in dual therapy in conjunction with the
same or different therapeutic agent that is applied topically.
Thus, one embodiment is a method for treating an ocular condition in a patient, the
method comprising placing a biodegradable intraocular implant according to this disclosure in
the eye(s) affected by the ocular condition, thereby treating the ocular condition in the eye(s).
The implant is preferably placed in the anterior chamber of the eye, but may be placed in the
posterior chamber (i.e. the region of the eye immediately behind the iris in the ciliary sulcus) or
vitreous body of the eye. Placement in the vitreous body (intravitreal placement) may be
preferred in patients with narrow anterior chamber angles such as those patients with Shaffer
Grade 1 or 2 angles, wherein the iris is closely approximated to the trabecular meshwork nearing
the threshold to start obstructing aqueous humor outflow resulting in an elevation of the
intraocular pressure. Shaffer Grade 1 and 2 patients should receive intravitreal implants rather
than an intracameral implant to reduce the chance of corneal toxicity. A Shaffer grade of 0 is
Docket No. 19235 (AP) PATENT
considered to be a closed angle, wherein the iris completely occludes the trabecular meshwork,
leading to high intraocular pressure and the potential for optic nerve damage and blindness.
Patients that can fit or tolerate maximal intracameral implant diameter swells of about 400 µm or
greater will generally have Shaffer Grade 3 to 4 (wide open) angles, whereas angles that are
Shaffer Grade 1 and 2 may only accommodate implants with a maximum diameter swell of
about 200 µm to less than about 400 µm.
The implant will preferably provide a therapeutically effective dose of the prostamide
to the eye(s) for at least two months after placement in the eye, and will reduce the ocular
condition, or at least one sign or symptom, or risk factor associated with the ocular condition, for
at least 1 month, or for at least 2, or 4 months following placement of the implant in the anterior
chamber of the eye. If desired, more than one implant can be placed in the eye. For example, two
implants may be placed in the anterior chamber or vitreous body of the eye to deliver a larger
dose of the prostamide. For example, in one method an eye may be dosed with 20 µg of
bimatoprost, by placing two 50-µg implants (each containing 20% bimatoprost by weight) in the
anterior chamber of the eye simultaneously rather than using a single 100-µg implant. Using two
smaller implants may possibly improve the tolerability of the implants in the eye and further
reduce the risk of an implant contacting the corneal endothelium, thereby lessening or altogether
eliminating the chance that the eye will experience a loss of corneal endothelial cell density and
onset of corneal edema.
One example of a prostamide-containing intraocular implant according to this
disclosure is an extruded intraocular implant comprising Formulation 2, as set forth in Table 1,
below. In some embodiments, an implant comprises any of Formulations 2-8 and is sized for
placement in the anterior chamber of the eye. The anterior chamber implant will preferably fit
within the anterior chamber angle without contacting or rubbing against the corneal endothelium
after placement in the eye.
As mentioned previously, examples of an ocular condition according to this method
include elevated intraocular pressure, ocular hypertension, and glaucoma, including, for example
open angle glaucoma or angle-closure glaucoma. While various prostamides may be delivered
with the present method, the implants described here are especially useful for the delivery of
(and will therefore contain as the sole active agent) bimatoprost.
Docket No. 19235 (AP) PATENT
One embodiment is a method for reducing ocular pressure in an eye of a mammal, the
method comprising placing a biodegradable intraocular implant according to this disclosure in an
eye of the mammal, whereby the implant provides a prostamide to the eye in an amount effective
for reducing ocular pressure in the eye. In some forms of this method the mammal is a human
patient that has elevated intraocular pressure, ocular hypertension, or glaucoma, and the implant
is placed in the anterior chamber of the affected eye(s) of the patient. The implant may be
effective for reducing intraocular pressure in the eye for at least two months after placement in
the anterior chamber of the eye. In some instances, the implant may reduce intraocular pressure
in the eye for 6-12 months or greater than 12 months after placement of the implant in the eye. In
one embodiment the prostamide provided by the implant is bimatoprost. Preferably, the implant
is sized and formulated for placement in the anterior chamber of the eye and does not contact
and/or does not injure the corneal endothelium after placement in the anterior chamber of an eye,
such as for example a human eye. Eliminating contact between the implant and the corneal
endothelium may reduce the risk of corneal endothelial cell density reduction and onset of
corneal edema in the eye.
The present disclosure also describes a method for reducing or lowering intraocular
pressure in a patient, the method comprising placing a biodegradable intraocular implant in an
eye of the patient, thereby reducing intraocular pressure in the eye for an extended period such
as, for example, for at least one month, two months, or for at least four months. In some
instances, the patient may have open-angle glaucoma, or more specifically primary open-angle
glaucoma, and/or ocular hypertension. The implant used in the method can be any of the
prostamide-containing implants described herein. In a preferred embodiment, the method
comprises placing an extruded intraocular implant comprising Formulation 2 in an eye of the
patient. The implant can be placed in the anterior chamber, vitreous body, or posterior chamber
of the eye, for example. In some instances, the implant may be specifically placed in the anterior
chamber angle (iridocorneal angle) of the eye, and even more specifically in the inferior
iridocorneal angle of the eye.
Examples of medically beneficial effects that may be produced by the present
treatment methods may include but are not limited to a reduction in intraocular pressure. In some
instances, the method may possibly retard or inhibit the progression of glaucoma or
Docket No. 19235 (AP) PATENT
glaucomatous damage in the eye, and/or retard or delay visual field loss in a patient, as compared
to patients that do not receive an implant.
The implants described herein may be inserted into the eye by a variety of methods
using a suitable ocular implant delivery device. One example may include the device disclosed in
U.S. Patent 6,899,717.
In one embodiment, the implant is placed in the eye(s) using an intraocular delivery
apparatus, the apparatus comprising an elongate housing and a cannula extending longitudinally
from the housing, the cannula having a proximal end and a distal sharp end and having a lumen
extending therethrough, the lumen having an inner diameter sufficient to receive the implant and
permit passage of the implant through the lumen and into the eye of the patient. The apparatus
may further comprise a push rod or plunger operably connected with a user-actuated linkage for
ejecting the implant through the lumen into the eye.
Another embodiment described herein is an apparatus for delivering a biodegradable
intraocular implant into the eye of a patient, the apparatus comprising an intraocular implant
according to any of those described herein, an elongate housing and a cannula extending
longitudinally from the housing, the cannula having a proximal end, a distal sharp end, and a
lumen extending therethrough, the lumen having an inner diameter sufficient to receive the
intraocular implant and permit translation of the implant through the lumen and into the eye of
the patient. The cannula may be a 25 gauge, 26 gauge, 27 gauge, 28 gauge, 29 gauge, or 30
gauge needle, or may otherwise be described as having inner and outer diameters equivalent to
those of a 25 gauge, 26 gauge, 27 gauge, 28 gauge, 29 gauge, or 30 gauge needle. The needle, in
addition, may be a thin-wall or ultra-thin-wall needle.
The present disclosure also describes methods of making a biodegradable intraocular
prostamide-containing implant that will release a therapeutically effective amount of a
prostamide in an eye for at least 60 days (two months). The method generally comprises
combining a prostamide, at least three biodegradable polymers, and optionally a polyethylene
glycol to form a combination of components, blending the combination to form a blended
mixture, heating the blended mixture, then extruding the heated mixture to form a filament, and
then cutting the filament to form an implant suitable for placement in an ocular region of an eye
of a patient. For example, the implant may be cut to a length suitable (sized) for placement in the
Docket No. 19235 (AP) PATENT
anterior chamber or vitreous body of the eye of the patient. Each of the components may be
combined as dry powders or as dry solids. The blending step may therefore comprise dry powder
blending. The at least three biodegradable polymers may be selected from the group consisting
of poly(D,L-lactide) (PLA) polymers and poly(D,L-lactide-co-glycolide) (PLGA) polymers. For
example, the at least three biodegradable polymers may consist of first, second, and third
biodegradable polymers that differ one from the other by their repeating unit, inherent viscosity,
and/or end-group. In some instances, the at least three biodegradable polymers may consist of
first, second, third, and fourth biodegradable polymers that differ one from the other. The first,
second, third, and, optionally fourth biodegradable polymers may be selected from acid-end and
ester-end PLA and PLGA polymers. For example, the first, second, third, and optionally fourth
biodegradable polymers used to make the implants according to the method described above may
be selected from the group consisting of RESOMER® Biodegradable Polymers R203S, R202H,
RG502, RG502H, RG752S, RG755S, and RG858S, wherein RG502 is a poly(D,L-lactide-co-
glycolide) having an ester end group and an inherent viscosity of 0.16-0.24 dl/g and a D,L-
lactide:glycolide ratio of about 50:50, RG502H is a poly(D,L-lactide-co-glycolide) having an
acid end group and an inherent viscosity of 0.16-0.24 dl/g, and a D,L-lactide:glycolide ratio of
about 50:50, and RG755S is an ester end poly(D,L-lactide-co-glycolide) having an inherent
viscosity of 0.50-0.70 dl/g and a D,L-lactide:glycolide ratio of about 75:25. In one embodiment
the polyethylene glycol is polyethylene glycol 3350 (PEG 3350).
Thus, one embodiment is a method for making a biodegradable intraocular implant
comprising mixing a prostamide with a) an ester end poly(D,L-lactide) having an inherent
viscosity of 0.25-0.35 dl/g, b) an acid end poly(D,L-lactide) having an inherent viscosity of 0.16-
0.24 dl/g, and c) an ester end poly(D,L-lactide-co-glycolide) having an inherent viscosity of
0.16-0.24 dl/g and a D,L-lactide to glycolide molar ratio of about 75:25, and with polyethylene
glycol 3350, extruding the mixture to form a filament, followed by cutting the filament to length
suitable for placement in the anterior chamber or vitreous body of an eye to thereby form an
intraocular implant, wherein the prostamide comprises about 20% of the implant by weight, the
ester end poly(D,L-lactide) comprises about 20% of the implant by weight, the acid end
poly(D,L-lactide) comprises about 15% of the implant by weight, the ester end poly(D,L-lactide-
Docket No. 19235 (AP) PATENT
co-glycolide) comprises about 40% of the implant by weight, and the polyethylene glycol 3350
comprises about 5% of the implant by weight.
A further embodiment is an intraocular biodegradable implant made by any of the
methods described above.
Unless otherwise specified the inherent viscosity for the PLA and PLGA polymers set
forth herein is measured for a 0.1% solution of the polymer in chloroform at 25ºC.
BRIEF DESCRIPTION OF THE DRAWINGS
shows the in vitro cumulative release of bimatoprost (as a percent of the total
amount of bimatoprost loaded in the implant) over time from an extruded implant having either
Formulation 1 or Formulation 2 (see Table 1), following placement of the implant in 0.01 M
phosphate buffered saline (pH 7.4) at 37°C. Each data point represents the average of 3 to 4
replicate samples. The implants in this study each weighed about 50 µg and had a length of about
1.05 mm and a diameter of about 200 µm.
and B show the change in diameter and length (i.e., the swelling) of an
extruded implant having either Formulation 1 or Formulation 2 over time in 0.01 M phosphate
buffered saline (pH 7.4) at 37°C. The starting weight of the implants was about 50 µg, and the
initial length and diameter of the implants in these studies were about 1.05 mm and about 200
µm, respectively.
shows the swelling and degradation of extruded implants having either
Formulation 1 or Formulation 2 in vitro over time following placement of the implants in
phosphate buffered saline (pH 7.4) at 37°C. The implant mages were recorded at a magnification
of 150X at various time points and the lengths and diameters were measured. Each implant was
initially 1.05 mm in length and 200 µm in diameter and the starting total weight of each implant
was about 50 µg.
shows the reduction in IOP in a dog eye following intracameral injection of a
bimatoprost-containing implant.
shows the change in pupil diameter in a dog eye over time following the
intracameral injection of a bimatoprost-containing implant.
Docket No. 19235 (AP) PATENT
shows the change in mean corneal endothelial cell density in an eye after
receiving an extruded bimatoprost-containing implant in the anterior chamber. One implant was
placed in the right eye of each dog in Groups 2, 3, 4, and 5. Each implant comprised Formulation
1 and contained 20, 30, 40, or 50 µg of bimatoprost, as shown in parentheses. The total weight of
the injected implant was approximately 5 times (5X) the weight of bimatoprost, since each
implant comprised about 20% bimatoprost by weight (see Formulation 1 in Table 1).
Accordingly, animals in Groups 2, 3, 4, and 5 received implants that weighed about 100, 150,
200, and 250 µg, respectively. The x-axis shows time from dosing.
shows a cross-section of the mammalian eye.
DETAILED DESCRIPTION
Definitions
For the purposes of this description, we use the following terms as defined in this
section, unless the context of the word indicates a different meaning.
The terms
As used herein, an "intraocular implant" and “intraocular drug delivery system” refers
to a device or element that is structured, sized, or otherwise configured to be placed in an eye and
that is capable of delivering a therapeutic level of a drug to the eye. Intraocular implants and
drug delivery systems in accordance with the present disclosure are generally biocompatible with
physiological conditions of an eye and do not cause adverse side effects or immunological
reaction. The implants are preferably completely biodegradable. Intraocular implants may be
placed in an eye without disrupting vision of the eye. Non-limiting examples include extruded
filaments or rods comprising a biodegradable polymer matrix and an active agent, such as
bimatoprost, associated with the polymer matrix, and having a diameter and cut to a length
suitable for placement in an ocular region of the eye, such as the anterior chamber.
An “intracameral implant” is an intraocular implant that is structured, sized, or
otherwise configured to be placed in the anterior chamber of an eye. The anterior chamber of the
eye refers to the fluid-filled space inside the eye between the iris and the innermost corneal
surface (corneal endothelium). An intracameral implant will preferably fit into the anterior
Docket No. 19235 (AP) PATENT
chamber angle, the junction of the front surface of the iris and back surface of the cornea,
without contacting the corneal endothelium and thereby without causing corneal trauma,
inflammation, or edema, or iris chaffing.
An "intravitreal" implant is an intraocular implant that is sized for placement in the
vitreous body of the eye.
As used herein, "associated with the biodegradable polymer matrix" can mean any
one or more of mixed with, dispersed within, coupled to, covering, or surrounding. Usually, the
prostamide is non-covalently associated with the polymer matrix and is dispersed within and/or
throughout the matrix.
As used herein, an "ocular region" or "ocular site" refers generally to any area of the
eyeball, including the anterior and posterior segment of the eye, and which generally includes,
but is not limited to, any functional (e.g., for vision) or structural tissues found in the eyeball, or
tissues or cellular layers that partly or completely line the interior or exterior of the eyeball.
Specific examples of ocular regions in the eye include the anterior chamber, the posterior
chamber, the vitreous cavity, the vitreous body, the choroid, the suprachoroidal space, the
conjunctiva, the subconjunctival space, the sub-tenon space, the episcleral space, the intracorneal
space, the epicorneal space, the sclera, the pars plana, surgically-induced avascular regions, the
macula, and the retina.
As used herein, an "ocular condition" is a disease, ailment or medical condition which
affects or involves the eye or one of the parts or regions of the eye. An ocular condition may be
classified as an anterior or posterior ocular condition. Broadly speaking the eye includes the
eyeball and the tissues and fluids which constitute the eyeball, the periocular muscles (such as
the oblique and rectus muscles) and the portion of the optic nerve which is within or adjacent to
the eyeball. Examples of an ocular condition within the scope of this disclosure include elevated
intraocular pressure, ocular hypertension, and glaucoma. Glaucoma in a patient may be further
classified as open-angle glaucoma or angle-closure glaucoma. A patient may be specifically
diagnosed with primary open-angle glaucoma.
An anterior ocular condition is a disease, ailment or condition which affects or which
involves an anterior (i.e. front of the eye) ocular region or site, such as a periocular muscle, an
eye lid or an eye ball tissue or fluid which is located anterior to the posterior wall of the lens
Docket No. 19235 (AP) PATENT
capsule or ciliary muscles. Thus, an anterior ocular condition primarily affects or involves the
conjunctiva, the cornea, the anterior chamber, the iris, the ciliary body, the posterior chamber,
the lens or the lens capsule and blood vessels and nerve which vascularize or innervate an
anterior ocular region or site. Glaucoma can also be considered to be an anterior ocular
condition because a clinical goal of glaucoma treatment can be to reduce a hypertension of
aqueous fluid in the anterior chamber of the eye (i.e. reduce intraocular pressure).
A posterior ocular condition is a disease, ailment or condition which primarily affects
or involves a posterior ocular region or site such as choroid or sclera (in a position posterior to a
plane through the posterior wall of the lens capsule), vitreous, vitreous chamber, retina, optic
nerve (i.e. the optic disc), and blood vessels and nerves which vascularize or innervate a
posterior ocular region or site. Glaucoma can also be considered a posterior ocular condition
because the therapeutic goal is to prevent the loss of or reduce the occurrence of loss of vision
due to damage to or loss of retinal cells or optic nerve cells (i.e. neuroprotection).
Intraocular pressure refers to the fluid pressure in the eye and is determined by the
difference in the rate of aqueous humor secretion and outflow. Approximately 90% of the
aqueous humor secreted exits through the trabecular meshwork in the anterior chamber.
Resistance to outflow can lead to elevated intraocular pressure. Some populations or patient
groups with normal tension (i.e., normotensive) glaucoma may have an IOP of from about 11 to
21 mm Hg. Some patient groups or patients with elevated intraocular pressure or ocular
hypertension may have an IOP of greater than 20 or 21 mm Hg, as measured with a tonometer.
Implants of the present disclosure are expected to be capable of reducing intraocular pressure in
both normotensive and hypertensive glaucoma patients.
The term "biodegradable polymer" and “biodegradable intraocular implant” refers to
a polymer or intraocular implant that degrade in vivo, and wherein erosion of the polymer or
implant over time occurs concurrent with or subsequent to release of the therapeutic agent. The
terms "biodegradable" and "bioerodible" are equivalent and are used interchangeably herein. A
biodegradable polymer may be a homopolymer, a copolymer, or a polymer comprising more
than two different polymeric units. Examples of biodegradable polymers within the scope of this
disclosure are poly(D,L-lactide) polymers and poly(D,L-lactide-co-glycolide) copolymers.
Docket No. 19235 (AP) PATENT
The terms "treat," "treating," or "treatment" as used herein, refers to reduction or
resolution or prevention of an ocular condition, ocular injury or damage, or to promote healing of
injured or damaged ocular tissue. A treatment may be effective to reduce at least one sign or
symptom of the ocular condition or risk factor associated with an ocular condition.
The term "therapeutically effective amount" as used herein, refers to the level or
amount of agent needed to treat an ocular condition, or reduce or prevent ocular injury or
damage without causing significant negative or adverse side effects to the eye or a region of the
eye.
"Active agent,” “drug,” “therapeutic agent,” “therapeutically active agent,” and
“pharmaceutically active agent” refer to the chemical compound that produces a therapeutic
effect in the patient to which it is administered and that can be used to treat the ocular condition
in the patient. One example of a therapeutically active agent and therapeutic agent in the context
of the present disclosure is bimatoprost. In preferred embodiments the therapeutic effect is an
intraocular pressure (IOP)-lowering effect, which can be identified by applying the compound to
an eye and evaluating whether the intraocular pressure decreases after application.
Unless further specified, a “patient” refers to a human subject or non-human mammal
in need of treatment for the ocular condition. For example, a patient may be further classified as
a human patient. The term “mammal” includes both human patients and non-human mammals.
Non-limiting examples of non-human mammals that may be subjects for any of the presently
disclosed methods can include horses, dogs, monkeys, pigs, rabbits, and the like.
The term “biocompatible” and “compatible” means compatible with living tissue or a
living system. Biocompatible implants and polymers produce few or no toxic effects, are not
injurious, or physiologically reactive with living tissue and do not cause an immunological
reaction.
“Cumulative release profile” means the cumulative total percent of an active agent
(such as bimatoprost) released from an implant into an ocular region in vivo over time or into a
specific release medium in vitro over time.
"Suitable (or configured) or sized for insertion, implantation, or placement in (or into)
an ocular region " with regard to an implant, means an implant which has a size (dimensions)
such that it can be inserted, implanted, or placed in an eye without causing excessive tissue
Docket No. 19235 (AP) PATENT
damage or physically impairing the existing vision of the patient into which the implant is
implanted or inserted.
[00081a] The term “comprising” as used in this specification and claims means “consisting
at least in part of”. When interpreting statements in this specification, and claims which include
the term “comprising”, it is to be understood that other features that are additional to the features
prefaced by this term in each statement or claim may also be present. Related terms such as
“comprise” and “comprised” are to be interpreted in similar manner.
Description
The presently disclosed intraocular implants may be effective in treating an ocular
condition in an eye of a patient, including an ocular condition associated with elevated
intraocular pressure, and more specifically in reducing at least one sign or symptom of, or risk
factor for glaucoma. The method generally comprises placing a biodegradable intraocular
implant in an ocular region of the eye(s) of the patient affected by the ocular condition. One
embodiment is a method for reducing intraocular pressure in a patient suffering from elevated
intraocular pressure, ocular hypertension, or glaucoma, comprising placing a prostamide-
containing biodegradable intraocular implant described herein in an eye of the patient to thereby
reduce intraocular pressure in the eye. Controlled and sustained administration of a prostamide
such as bimatoprost to the eye through the use of one or more of the intraocular prostamide-
containing implants described here may improve glaucoma treatment by reducing intraocular
pressure in a patient suffering from glaucoma or ocular hypertension for an extended period of
time, such as for 4, 5, or 6 months or more following placement of the implant in the eye.
Injection of one or two implants of the present disclosure into an eye of a patient may possibly
reduce the diurnal fluctuation in intraocular pressure (IOP) in the eye for about two months or
longer as compared to the diurnal fluctuation in an eye treated with once daily topical
administration of bimatoprost to an eye.
As described above, the implants comprise or consist of a prostamide and a
biodegradable polymer matrix that is formulated to release the prostamide over an extended
period of time, such as 60 days or longer. A polyethylene glycol, such as PEG 3350, may
Docket No. 19235 (AP) PATENT
optionally be included in the implant. The prostamide may comprise a compound having
Formula I. In a preferred embodiment the prostamide is bimatoprost.
The intraocular implants are intended to provide a therapeutically effective amount of
the prostamide directly to an ocular region of the eye, preferably the anterior chamber, for 2-4
months or longer. Thus, with a single administration of the implant, a therapeutically effective
amount of a prostamide will be made available at the site where it is needed and will be
maintained for an extended period of time, rather than subjecting the patient to repeated
injections or, in the case of self-administered eye drops, the burden of daily dosing.
The implant may be monolithic, i.e. having the active agent (for example
bimatoprost) homogenously distributed throughout the polymeric matrix. Alternatively, the
active agent may be distributed in a non-homogenous pattern in the polymer matrix. For
example, an implant may include a portion that has a greater concentration of the prostamide
compound relative to a second portion of the implant.
One example of an intraocular implant (i.e., drug delivery system) within the scope of
the present disclosure is an extruded biodegradable intraocular implant sized for implantation in
the anterior chamber of an eye, the implant comprising or consisting of 20% by weight (w/w)
bimatoprost, 5% by weight PEG 3350, 20% by weight R203S, which is an ester-end poly(D,L-
lactide) polymer having an inherent viscosity of 0.25-0.35 dl/g, 15% by weight R202H, which is
an acid-end poly(D,L-lactide) polymer having an inherent viscosity of 0.16-0.24 dl/g, and 40%
by weight RG752S, which is an ester-end poly(D,L-lactide-co-glycolide) polymer having a D,L-
lactide:glycolide molar ratio of about 75:25 and an inherent viscosity of 0.16-0.24 dl/g, wherein
the inherent viscosity of each polymer is measured for a 0.1% w/v solution in chloroform at
°C. The implant may sustain release of a therapeutically effective amount of the bimatoprost
into an eye for a period of two months or longer.
In some embodiments the intraocular implant is sized and formulated for placement
in the anterior chamber of the eye (i.e., for intracameral administration). An implant sized for
placement in the anterior chamber of an eye and capable of delivering a therapeutically effective
amount of bimatoprost to the mammalian eye for an extended period according to this disclosure
is generally from 20 µg to 200 µg in total weight, from 0.5 to about 3.0 mm in length, and from
0.1 to 0.5 mm in diameter (or other smallest dimension as may be appropriate for non-cylindrical
Docket No. 19235 (AP) PATENT
implants). In some embodiments, an implant sized for placement in the anterior chamber (an
intracameral implant) may weigh (therefore have a total weight) from about 30 to about 150 µg
and contain from about 6 µg to about 30 µg of bimatoprost or other prostamide. In a preferred
embodiment, the intracameral implant has a total weight of from 30 to 150 µg and is 150 µm to
300 µm in diameter and 0.5 mm to 2.5 mm in length. In a more preferred embodiment the
biodegradable intracameral implant according to this disclosure has a total weight of 30 µg to
100 µg and is 150 µm to 300 µm in diameter and 0.5 mm to 2.5 mm in length. In some
embodiments, the implant is about 150 to about 300 µm in diameter or width, about 1.0 mm to
about 2.5 mm in length, and about 30 µg to about 100 µg in total weight. In some embodiments,
the implant is 150 to about 300 µm in diameter or width, 1.0 mm to 2.5 mm in length, and 30 µg
to 75 µg, or 30 to 90 µg in total weight. The implant may be an extruded implant (i.e., the
implant may be produced by an extrusion process). In some embodiments, the implant is formed
by an extrusion process and is 150 to 300 µm in diameter or width, 0.50 to 2.5 mm in length, and
to 100 µg in total weight.
Thus, an intracameral implant according to this disclosure may have a total weight of
from 20-120 µg, 30-100 µg, 30-90 µg, 30-75 µg, or 30-50 µg. Non-limiting examples include
extruded implants containing about 6 µg, 10 μg, 15 μg, or 20 μg (±5%) bimatoprost and having a
total weight of about 30 µg, 50 µg, 75 μg, or 100 µg (±5%), respectively. In certain forms the
extruded implant may have a diameter of about 200 µm or 250 µm (±5%) (before placement in
the eye or other liquid or fluid environment) and a length of about 2.3 mm, 1.5 mm, or 1.0 mm
(±5%). Preferably, the implant can be received in, and injected into the eye through, a 27, 28, or
gauge ultra-thin-wall needle. Small diameter needles such as these may be desirable for
delivery of implants into the anterior chamber of the eye. Implants of the particular size
described here may have the additional advantage of fitting within the anterior chamber angle of
the eye without causing corneal trauma (e.g. edema) and without chaffing the iris. In one
embodiment the intracameral implant is about 200 µm to about 300 µm in diameter, and about
1.0 to about 2.3 mm in length. An implant sized for placement in the anterior chamber of an eye
according to this disclosure and according to any of the foregoing embodiments can comprise
% (w/w) bimatoprost, 20% (w/w) R203S, 15% (w/w) R202H, 40% (w/w) RG752S, and 5%
(w/w) polyethylene glycol (PEG) 3350. Implants are sized and formulated for placement in the
Docket No. 19235 (AP) PATENT
anterior chamber in accordance with this disclosure so as to avoid contact with the corneal
endothelium (i.e., so that the implant does not contact the corneal endothelium) after placement
in the anterior chamber of an eye. Contact with the corneal endothelium may result in a loss of
corneal endothelial cells (density reduction) and onset of corneal edema. The risk for such
adverse effects generally rises with increasing size of the implant. With larger implants there is a
greater likelihood of contact with the corneal endothelium, e.g., by touching the endothelium
anterior to Schwalbe’s line.
One embodiment is an extruded biodegradable intraocular implant according to this
disclosure that is sized for placement in the anterior chamber of the eye, whereby the implant is
150 to 300 µm in diameter, 0.50 to 3 mm in length, and 25 to 100 µg in total weight. Another
embodiment is an extruded biodegradable intraocular implant according to this disclosure that is
sized for placement in the anterior chamber of the eye, whereby the implant is 150 to 250 µm
(±5%) in diameter, 0.75 to 2 mm in length, and 50 to 75 µg in total weight. The implant
according to either embodiment will usually comprise 20% by weight bimatoprost as the active
agent in association with a biodegradable polymer matrix comprising or consisting of i) an ester-
end poly(D,L-lactide), ii) an acid-end poly(D,L-lactide), and iii) an ester-end poly(D,L-lactide-
co-glycolide) having a D,L-lactide:glycolide ratio of about 75:25 and an inherent viscosity of
0.16-0.24 dl/g, wherein the inherent viscosity is measured for a 0.1% solution of the polymer in
chloroform at 25°C. In a more specific embodiment, the ester end poly(D,L-lactide) has an
inherent viscosity of 0.25-0.35 dl/g and the acid-end poly(D,L-lactide) has an inherent viscosity
of 0.16-0.24 dl/g.
The vitreous body of the eye may be able to accommodate relatively larger implants
with total weights ranging from 250-5000 µg, and with diameters ranging from 0.5 mm to 3 mm
and lengths ranging from 5 to 10 mm. If desired, an implant sized for placement in the anterior
chamber may also be used for placement in the vitreous body of an eye.
The size and geometry of the implant can also be used to control the rate of release,
period of treatment, and drug concentration at the site of implantation. Larger implants will
deliver a proportionately larger dose, but depending on the surface to mass ratio, may have a
slower release rate. The particular size and shape of the implant are chosen to suit the site of
Docket No. 19235 (AP) PATENT
implantation, and may also be consistent with the size of the needle used to inject the implant
into the eye.
The implants described herein may be produced in a variety of shapes, including as a
rod, sheet, film, wafer, or compressed tablet, but are preferably in the form of an extruded rod.
An extruded rod may be cylindrical or non-cylindrical in shape. The implants may be monolithic,
i.e. having the active agent or agents homogenously distributed through the polymeric matrix.
An implant according to this disclosure may desirably provide a substantially
constant rate of prostamide release from the implant over the life of the implant. For example, it
may be desirable for the prostamide to be released in an amount between 0.01 µg and 2 µg per
day until 80-100% of the drug load has been released. However, the release rate may change to
either increase or decrease depending on the formulation of the biodegradable polymer matrix.
In addition, the release profile of the prostamide component may include one or more linear
portions.
A therapeutically effective amount of bimatoprost for reducing intraocular pressure in
an eye of a patient may correspond to a bimatoprost release rate in the eye of about 50 to 500
ng/day. An implant according to Formulation 2, for example (Table 1), with a total weight of
about 25 µg and comprising about 20% by weight bimatoprost (i.e., about 5 µg of bimatoprost)
may release approximately 50 ng of bimatoprost per day following placement in the eye. A
Formulation 2 implant having a total weight of about 250 µg and comprising about 50 µg of
bimatoprost may release approximately 500 ng of bimatoprost per day following placement in
the eye.
Release of the prostamide from a biodegradable polymer matrix may be a function of
several processes, including diffusion out of the polymer, degradation of the polymer and/or
erosion or degradation of the polymer. Some factors which influence the release kinetics of
active agent from the implant can include the size and shape of the implant, the size of the active
agent particles, the solubility of the active agent, the ratio of active agent to polymer(s), the
method of manufacture, the surface area exposed, and the erosion rate of the polymer(s). For
example, polymers may be degraded by hydrolysis (among other mechanisms), and therefore,
any change in the composition of the implant that enhances water uptake by the implant will
likely increase the rate of hydrolysis, thereby increasing the rate of polymer degradation and
Docket No. 19235 (AP) PATENT
erosion, and thus, increasing the rate of active agent release. Equally important to controlling the
biodegradation of the polymer and hence the extended release profile of the implant is the
relative average molecular weight of the polymeric composition employed in the implant.
Different molecular weights of the same or different polymers may be included in an implant to
modulate the release profile.
The release kinetics of the implants described herein can be dependent in part on the
surface area of the implants. A larger surface area may expose more polymer and active agent to
ocular fluid, and may cause faster erosion of the polymer matrix and dissolution of the active
agent particles in the fluid. Therefore, the size and shape of the implant may also be used to
control the rate of release, period of treatment, and active agent concentration at the site of
implantation. As discussed herein, the matrix of the intraocular implant may degrade at a rate
effective to sustain release of an amount of bimatoprost or other prostamide for two months after
implantation into an eye.
The release rate of an active agent, such as bimatoprost, from an implant may be
empirically determined using a variety methods. A USP approved method for dissolution or
release test can be used to measure the rate of release (USP 23; NF 18 (1995) pp. 1790-1798).
For example, using the infinite sink method, a weighed sample of the drug delivery system (e.g.,
implant) is added to a measured volume of a solution containing 0.9% NaCl in water (or other
appropriate release medium such as phosphate buffered saline), where the solution volume will
be such that the drug concentration after release is less than 20%, and preferably less than 5%, of
saturation. The mixture is maintained at 37°C and stirred slowly to ensure drug release. The
amount of drug released in to the medium as a function of time may be quantified by various
methods known in the art, such as spectrophotometrically, by HPLC, mass spectroscopy, etc.
The intraocular implants described here comprise a mixture of at least three different
biodegradable polymers selected from the group consisting of poly(D,L-lactide) (PLA) polymers
and poly(D,L-lactide-co-glycolide) (PLGA) polymers. Differences between the three polymers
may be with regard to the end group, inherent viscosity, or repeating unit, or any combination
thereof.
Poly (D,L-lactide), or PLA, may be identified by CAS Number 266804, and may
be represented by the formula:
Docket No. 19235 (AP) PATENT
Poly(D,L-lactide-co-glycolide), or PLGA, may be identified by CAS Number 26780-
50-7, and may be represented by the formula:
O O *
Thus, poly(D,L-lactide-co-glycolide) comprises one or more blocks of D,L-lactide
repeat units (x) and one or more blocks of glycolide repeat units (y), where the size and number of
the respective blocks may vary. The molar percent of each repeat unit in a poly(lactide-co-
glycolide) (PLGA) copolymer may be independently 0-100%, 50-50%, about 15-85%, about 25-
75%, or about 35-65%. In some embodiments, the D,L-lactide may be about 50% to about 85%
of the PLGA polymer on a molar basis. The balance of the polymer may essentially be the
glycolide repeat units. For example, the glycolide may be about 15% to about 50% of the PLGA
polymer on a molar basis.
More specifically the at least three different biodegradable polymers included in an
intraocular implant according to this disclosure are independently selected from the group
consisting of:
Docket No. 19235 (AP) PATENT
a) a poly(D,L-lactide) having an acid end group and an inherent viscosity of 0.16-
0.24 dl/g, as measured for a 0.1% solution in chloroform at 25ºC (such as for
example R202H);
b) a poly(D,L-lactide) having an ester end group and an inherent viscosity of 0.25-
0.35 dl/g, as measured for a 0.1% solution in chloroform at 25ºC (such as for
example R203S);
c) a poly(D,L-lactide-co-glycolide) having an acid end group, an inherent viscosity
of 0.16-0.24 dl/g (as measured for a 0.1% solution in chloroform at 25ºC), and a
D,L-lactide:glycolide molar ratio of about 50:50 (such as for example RG502H);
d) a poly(D,L-lactide-co-glycolide) having an ester end group, an inherent viscosity
of 0.16-0.24 dl/g (as measured for a 0.1% solution in chloroform at 25ºC), and a
D,L-lactide:glycolide molar ratio of about 50:50 (such as for example RG502);
e) a poly(D,L-lactide-co-glycolide) having an ester end group, an inherent viscosity
of 0.16-0.24 dl/g (as measured for a 0.1% solution in chloroform at 25ºC), and a
D,L-lactide:glycolide molar ratio of about 75:25 (such as for example RG752S);
f) a poly(D,L-lactide-co-glycolide) having an ester end group, an inherent viscosity
of 0.50-0.70 dl/g (as measured for a 0.1% solution in chloroform at 25ºC), and a
D,L-lactide:glycolide molar ratio of about 75:25 (such as for example RG755S);
g) a poly(D,L-lactide-co-glycolide) having an ester end group, an inherent viscosity
of 1.3-1.7 dl/g (as measured for a 0.1% solution in chloroform at 25ºC), and a
D,L-lactide:glycolide molar ratio of about 85:15 (such as for example RG858S).
Unless otherwise specified, the inherent viscosities of the PLA and PLGA polymers
referred to in this disclosure are determined for a 0.1% (w/v) solution of the polymer in
chloroform (CHCl ) at 25°C. Biodegradable PLA and PLGA polymers, such as the
RESOMER® Biodegradable Polymers R203S, R202H, RG752S, RG755S, and RG858S, are
available commercially from sources such as Evonik Industries, AG, Germany (Evonik Rohm
Pharma GmbH), and Sigma-Aldrich.
Bimatoprost is described in, for example, U.S. Patent 6,403,649 and 5, 688,819.
Docket No. 19235 (AP) PATENT
In addition to bimatoprost and the at least three different biodegradable polymers, some
implants according to this disclosure further include a polyethylene glycol having a molecular
weight of 300 Da to 20,000 Da. For example, an implant may comprise polyethylene glycol 3350
(PEG 3350), or alternatively polyethylene glycol 20,000 (PEG 20K).
The prostamide component of the implant may be in a particulate or powder form and
it may be entrapped by, embedded within, or distributed uniformly or non-uniformly throughout
the biodegradable polymer matrix. In the presently disclosed implants, the prostamide will usually
comprise about 20% of the implant on a weight to weight (w/w) basis. In other words, the
prostamide will constitute about 20% of the implant by weight. More generally, the prostamide
can comprise (i.e., be present in an amount of or constitute) 18% and 22% of the implant by weight.
In addition to bimatoprost or other prostamide, the intraocular implants and other drug
delivery systems (e.g., microspheres) disclosed herein may optionally include one or more
buffering agents, preservatives, antioxidants, or other excipients, or combinations thereof. Suitable
water soluble buffering agents include, without limitation, alkali and alkaline earth carbonates,
phosphates, bicarbonates, citrates, borates, acetates, succinates and the like, such as sodium
phosphate, citrate, borate, acetate, bicarbonate, carbonate and the like. These agents are
advantageously present in amounts sufficient to maintain a pH of the system of between 2 to 9 and
more preferably 4 to 8. Suitable water soluble preservatives include sodium bisulfite, sodium
bisulfate, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal,
phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, parabens, methylparaben,
polyvinyl alcohol, benzyl alcohol, phenylethanol and the like and mixtures thereof. These
buffering agents, preservatives, antioxidants, and other excipients may be present in amounts of
from 0.001 to 10% by weight of the implant.
Examples of antioxidant agents include ascorbate, ascorbic acid, alpha-tocopherol,
mannitol, reduced glutathione, various carotenoids, cysteine, uric acid, taurine, tyrosine,
superoxide dismutase, lutein, zeaxanthin, cryptoxanthin, astaxanthin, lycopene, N-acetyl-cysteine,
carnosine, gamma-glutamylcysteine, quercitin, lactoferrin, dihydrolipoic acid, citrate, Ginkgo
Biloba extract, tea catechins, bilberry extract, vitamins E or esters of vitamin E, and retinyl
palmitate.
Docket No. 19235 (AP) PATENT
An implant described herein may comprise a single type of prostamide compound (for
example, bimatoprost) as the sole active agent or may comprise a combination of two or more
prostamides.
The biodegradable implants described herein may be sterilized by gamma or by
electron-beam radiation and inserted or placed into the anterior chamber or vitreous body of an
eye by a variety of methods and devices, including needle-equipped delivery devices capable of
ejecting the implant into the ocular region of the eye. An effective dose of radiation for sterilization
may be about 20-30 kGy. One example of a device that may be used to insert an implant into an
eye is disclosed in U.S. Patent No. 6,899,717. The ocular applicator or injection device will
generally comprise an appropriately sized needle. Smaller needles are preferred to minimize
trauma to the eye (for example, a 25, 27, 28, or 30 gauge needle). In some embodiments, the hand
held applicator comprises an 25-30 gauge stainless steel needle, a lever, an actuator, and a plunger
or push rod to promote ejection of the implant from the device into the eye. Some embodiments
comprise placing two implants in an ocular region of the eye, such as for example the anterior
chamber or vitreous body of the eye.
To provide for the intended therapeutic effect (e.g., long term reduction of intraocular
pressure) in a patient, including one suffering from glaucoma, an implant according to the present
disclosure can be placed in the anterior chamber of the eye. The anterior chamber refers to the
space inside the eye between the iris and the innermost corneal surface (endothelium). In some
patients, however, such as those with a narrow anterior chamber angle, it may be preferable to
place the implant in the vitreous body of the eye. Other possible locations for an implant include
the subconjunctival space, subTenon’s space, and the posterior chamber, which is the space inside
the eye between the back of the iris and the front face of the vitreous. The posterior chamber
includes the space between the lens and the ciliary processes, which produces the aqueous humor
that nourishes the cornea, iris, and lens and maintains intraocular pressure. Referring to Figure 7,
these and other ocular regions of the eye (100) are shown in cross-section. Particular regions of
the eye (100) include the cornea (102) and iris (104), which surround the anterior chamber (106).
Behind the iris (104) is the posterior chamber (108) and lens (110). Within the anterior chamber is
the anterior chamber angle (112) and trabecular meshwork (114). Also shown are the corneal
Docket No. 19235 (AP) PATENT
epithelium (118), sclera (116), vitreous (119), ciliary zonules (120), and ciliary process (121). The
posterior segment of the eye is the rear two-thirds of the eyeball (behind the lens), and includes
the vitreous, the retina, and the optic nerve.
The method of implantation may involve accessing the target area within the ocular
region with the needle, or implantation device. Once within the target area, e.g., the anterior
chamber or vitreous cavity, a lever on a hand held device can be depressed to cause an actuator to
drive a plunger or push rod or other suitable means forward. As the plunger moves forward, it can
push the implant or implant into the target area. The location of the implant may influence the
concentration gradients of drug surrounding the implant, and thus influence the release rates (e.g.,
an implant placed in the vitreous, a viscous gel, may result in a slower release rate compared with
placement in the aqueous humor (i.e. non-viscous water)). In some forms of the method for treating
a patient according to this disclosure it may be desirable to place the implant in the anterior
vitreous. For vitreous placement, the anterior vitreous may be ideal since it remains viscous
throughout a patient’s life time. As a result, this viscous environment entraps the implant and
maintains the implant adjacent to the target tissues (i.e. ciliary body) to maximize the prostamide
pharmacologic activity. In contrast, the posterior vitreous can liquefy with age and does not
necessarily provide reasonable implant proximity to the ciliary body to optimize the
pharmacologic performance of the implant.
Various techniques may be employed to make biodegradable intraocular implants.
Useful techniques include extrusion methods (for example, hot melt extrusion), compression
methods, pellet pressing, solvent casting, print technology, hot embossing, soft lithography
molding methods, injection molding methods, heat press methods and the like. As previously
discussed, a biodegradable intraocular implant according to this disclosure may be configured as
a rod, wafer, sheet, film, or compressed tablet. Cast films or sheets can be ground into
microparticles, which may be useful in some applications. Biodegradable microspheres formed by
an emulsion method and having any of the formulations described herein may also find use in a
method according to this disclosure.
Preferably the intraocular implant of this disclosure is a solid rod-shaped implant
formed by an extrusion process (an extruded rod) and is sized for placement in the anterior chamber
Docket No. 19235 (AP) PATENT
of the eye. Methods for making a bimatoprost-containing intraocular implant by an extrusion
process are familiar to those of skill in the art. See, for example, US 2008/0145403 and US
2005/0244464. An extruded implant (e.g., an extruded rod) can be made by a single or double
extrusion method. Choice of technique, and manipulation of technique parameters employed to
produce the implants can influence the release rates of the drug. Room temperature compression
methods may result in an implant with discrete microparticles of drug and polymer interspersed.
Extrusion methods may result in implants with a progressively more homogenous dispersion of
the drug within a continuous polymer matrix, as the production temperature is increased. The use
of extrusion methods may allow for large-scale manufacture of implants and result in implants
with a homogeneous dispersion of the drug within the polymer matrix.
The temperature used during an extrusion method should be high enough to soften the
polymer but low enough to avoid substantial loss of prostamide activity. In this regard, extrusion
methods may use temperatures of 50°C to 130°C, but more preferably the extrusion temperature
is between 50°C and 80°C, or even more preferably from 55°C to 70°C, particularly for the
production of implants comprising bimatoprost. For example, the extrusion temperature used to
make a bimatoprost-containing implant or other prostamide-containing implant may be 60°C to
75°C, or from 60°C to 70°C. Low temperatures such as these may be preferred for a variety of
prostamides, including bimatoprost, to best preserve their potency through to the final extruded
implant.
Different extrusion methods may yield implants with different characteristics,
including but not limited to the homogeneity of the dispersion of the active agent within the
polymer matrix. For example, using a piston extruder, a single screw extruder, and a twin screw
extruder may produce implants with progressively more homogeneous dispersion of the active
agent. When using one extrusion method, extrusion parameters such as temperature, feeding rate,
circulation time, pull rate (if any), extrusion speed, die geometry, and die surface finish will have
an effect on the release profile of the implants produced.
In one variation of producing implants by a piston or twin-screw extrusion methods,
the drug and polymers, including any polyethylene glycol if called for, are first mixed at room
temperature and then heated to an appropriate temperature to soften the mixture or transform the
Docket No. 19235 (AP) PATENT
mixture to a semi-molten state for a time period of 0 to 1 hour, for 1 to 10 minutes, 1 minute to 30
minutes, 1-5 minutes, 5 minutes to 15 minutes, or 10 minutes. The implants are then extruded at
a temperature of between 50°C and 80°C. In some variations, the temperature of extrusion may
range from 60-75°C, or from 60-65°C. In some screw extrusion methods, the powder blend of
active agent and polymer is added to a single or twin screw extruder preset at a temperature of
50°C to 130°C, and directly extruded as a filament or rod with minimal residence time in the
extruder. The extruded filament is then cut to a length suitable for placement in the anterior
chamber or vitreous of the eye. The total weight of the implant will of course be proportional to
the length and diameter of the implant, and implants may be cut to a desired target weight and
therefore dosage of the bimatoprost. For example, an intracameral implant in accordance with this
disclosure may be cut to a target weight of between 20 and 150 µg (±5%). In some embodiments,
the implants are cut to a target weight of 50 µg (±5%), 75 µg (±5%), or 100 µg (±5%), wherein
% of the implant by weight is bimatoprost.
Compression methods may use pressures of 50-150 psi, more preferably 70-80 psi,
even more preferably about 76 psi, and use temperatures of 0°C to 115°C, more preferably about
°C.
In one embodiment, the method for making the implants involves dissolving the
appropriate polymers and therapeutic prostamide in a solvent. Solvent selection will depend on
the polymers and therapeutic agents chosen. For the implants described herein, including a
therapeutic agent such as bimatoprost, dichloromethane (DCM) is an appropriate solvent. Other
solvents may include methylene chloride and ethyl acetate. Once the polymers and therapeutic
agent(s) have been dissolved, the resulting mixture is cast into a die of an appropriate shape. Once
cast, the solvent used to dissolve the polymers and therapeutic agent(s) is evaporated at a
temperature between 20°C and 30°C, preferably about 25°C. The polymer can be dried at room
temperature or even in a vacuum. For example, the cast polymers including therapeutic agents can
be dried by evaporation in a vacuum. Once the cast polymers are dried, they can be processed into
an implant using any method known in the art to do so. In an example embodiment, the dried
casted polymer can be cut and/or ground into small pieces or particles and extruded into rounded
or squared rod shaped structures at a temperature between 50°C and 80°C.
Docket No. 19235 (AP) PATENT
Compared with existing implants, an implant described herein is preferably
substantially completely degraded in less than 5 months, less than 10 months, or less than 12
months after placement in an eye. An implant is substantially completely degraded when no more
than 5% of the original mass of the implant remains in the eye or when the molecular weight of
the degraded polymers falls below 1000 Daltons. The rate of degradation and consequently the
predicted lifetime of an implant in vitro may, for example, be measured for the implant in 0.01M
PBS (pH 7.4) under constant shaking at 37°C.
Compared with existing implants, an implant described herein, when placed in an eye,
preferably swells to a diameter no greater than four times its original diameter and/or to a length
no greater than two times its original length.
An intraocular implant of this disclosure, whether placed in the anterior chamber or
vitreous of the eye, may be effective in reducing intraocular pressure in the eye for 2-6 months or
for 2-9 months, or even for 2-12 months or longer after placement in the eye without causing
corneal edema. One embodiment includes a method for delaying, slowing, or inhibiting visual
field loss or for improving vision in an eye of a patient with glaucoma comprising placing a
biodegradable intraocular implant according to this disclosure in the anterior chamber or vitreous
body of the eye, thereby reducing intraocular pressure in the eye continuously for 4-12 months or
6-12 months.
The present disclosure describes a biodegradable intraocular implant for reducing
intraocular pressure (IOP) in an eye comprising a biodegradable polymer matrix, polyethylene
glycol 3350, and a prostamide as the active agent, wherein the prostamide and polyethylene
glycol 3350 are associated with the biodegradable polymer matrix, which comprises an ester end
poly(D,L-lactide) having an inherent viscosity of 0.25-0.35 dl/g, an acid end poly(D,L-lactide)
having an inherent viscosity of 0.16-0.24 dl/g, and an ester end poly(D,L-lactide-co-glycolide)
having an inherent viscosity of 0.16-0.24 dl/g and a D,L-lactide to glycolide molar ratio of about
75:25, wherein the prostamide constitutes 18 to 22% of the implant by weight, the ester end
poly(D,L-lactide) constitutes 18 to 22% of the implant by weight, the acid end poly(D,L-lactide)
constitutes 13.5 to 16.5% of the implant by weight, the ester end poly(D,L-lactide-co-glycolide)
constitutes 36 to 44% of the implant by weight, and wherein the polyethylene glycol 3350
Docket No. 19235 (AP) PATENT
constitutes 3.5 to 6.5% of the implant by weight, wherein the inherent viscosity of each of the
poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers is determined for a 0.1% solution
of the polymer in chloroform at 25°C. In a specific embodiment the prostamide constitutes 20%
of the implant by weight, the ester end poly(D,L-lactide) constitutes 20% of the implant by
weight, the acid end poly(D,L-lactide) constitutes 15% of the implant by weight, the ester end
poly(D,L-lactide-co-glycolide) constitutes 40% of the implant by weight, and the polyethylene
glycol 3350 constitutes 5% of the implant by weight.
In some embodiments the implant defined above is rod-shaped and is formed by a
hot-melt extrusion process such that the formed implant is 150 to 300 µm in diameter or width,
0.50 to 2.5 mm in length, and 30 to 100 µg in total weight, whereby the implant does not contact
the corneal endothelium after placement in the anterior chamber of an eye. The implant is
preferably effective for reducing intraocular pressure in an eye for 2 months or longer after
placement in the eye. In one form of the implant, the prostamide is bimatoprost.
[000122a] In the description in this specification reference may be made to subject matter
that is not within the scope of the claims of the current application. That subject matter should be
readily identifiable by a person skilled in the art and may assist in putting into practice the
invention as defined in the claims of this application.
Example
Manufacture and testing of intracameral implants comprising
bimatoprost and a biodegradable polymer matrix
We set out to identify a solid biodegradable intracameral implant that would not only
release a therapeutically effective level of bimatoprost for an extended period (preferably two
months or longer) but one that would also fit into the anterior chamber angle of the eye without
injuring the corneal endothelium or chaffing the iris. We realized that it was important to avoid
injuring the corneal endothelium as this can lead to inflammation and possibly corneal opacity
and corneal edema, due possibly to mechanical trauma to the corneal endothelium by the
Docket No. 19235 (AP) PATENT
implant. Accordingly, the size of the implant and therefore the diameter (or width) and length of
the implant were carefully considered during the development of the implant.
Other properties considered included 1) the rate and duration of drug release from the
implant; a linear drug release profile is preferred; 2) the extent to which the implant swells when
placed in aqueous media (as compared to the initial size of the implant); polymer formulations
that take on or absorb less fluid are more likely to fit into the anterior chamber angle and remain
compatible with this space during the lifetime of the implant; and 3) the time it takes for the
implant to completely degrade after drug release is completed (i.e., the biodegradation time of
the implant). Ideally, the implant does not linger in the eye long after its drug supply is depleted,
but is degraded and eliminated from the eye soon after its drug supply has been exhausted.
Bimatoprost intracameral implants in this study were made by hot melt extrusion in a
Haake or DSM twin-screw microcompounder/extruder. Other possible methods may include
direct compression, single-screw extrusion, solvent casting, injection molding, soft lithography,
hot embossing, and print technology. The extruded implants in this study were rod-shaped, but
they can be made into any geometric shape by changing the extrusion or compression die.
Biodegradable polymers (such as the RESOMER® polymers, designated by polymer number in
the Tables below) were used as received from polymer suppliers, such as Evonik Industries.
The implants were made by combining bimatoprost with the biodegradable polymers
in a stainless steel container with two 10-mm stainless steel balls and mixed for 15 minutes in a
Turbula mixer. The container was removed from the mixer and the powder blend was stirred
with a spatula. The powder blend was inspected for homogeneity and the mixing procedure was
repeated. The twin-screw microcompounder/extruder was set up according to the manufacturer’s
instructions. The output of the extruder was fitted with a laser micrometer and a puller to control
the thickness of the extruded filament. The twin-screw microcompounder/extruder was allowed
to equilibrate to the extrusion temperature; then the powder blend was fed into the extrusion
screws at a rate that maintained a constant load and torque. A filament was extruded into a guide
mechanism and cut into individual implants (rods) with a specific length so as to obtain a desired
target weight (±5%) and drug dosage for the implant. For example, implants containing 10 μg,
Docket No. 19235 (AP) PATENT
μg, and 20 μg bimatoprost can be made by cutting the extruded filaments to a target weight of
50 ± 2.5 μg (5%), 75 ± 3.75 μg (5%), and 100 ± 5 μg (5%), respectively.
Tables 1 and 2 summarize the drug and polymer composition (Formulation) of some
of the implants made and tested during this study. Formulation 1 has been previously described
in US Patent Application Publication 2011/0182966. Table 3 summarizes results for some of the
implants. For each implant we measured 1) the rate of bimatoprost release from the implant in
vitro over time into a release medium consisting of 0.01M phosphate buffered saline (PBS), pH
7.4, at 37°C (calculated and plotted for replicate implants as the percent average total
bimatoprost release over time), 2) the degree and extent of implant swelling over time in 0.01M
phosphate buffered saline (PBS), pH 7.4 at 37°C, and 3) the rate of implant degradation in
0.01M phosphate buffered saline (PBS), pH 7.4 at 37°C. The estimated in vitro lifetime of an
implant was determined for each implant formulation based on the degradation results. For in
vivo testing the implants were placed in a vial and sterilized by a gamma radiation dose of 25 to
40 kGy.
Previous studies had taught us that implants containing more than 30% by weight
bimatoprost often produce a “burst” of bimatoprost release upon immersion in a specific release
medium such as PBS. On the other hand, for implants containing less than 20% by weight
bimatoprost, the release of bimatoprost is sometimes delayed resulting in an undesirable lag
period between the time the implant is placed in release medium and the time significant
quantities of bimatoprost begin appearing in the medium. Accordingly, for purposes of
formulating the intracameral sustained release implant and obtaining the desired target drug
release profile, all implants prepared for this study contained 20% by weight bimatoprost.
As shown by the results below, we identified a polymer formulation (Formulation No.
2) that can provide for the sustained release of bimatoprost in vitro at a near linear rate
(approximately half-order release kinetics) for approximately 60 days without an initial burst
effect or lag period (Figure 1). The release rate is slightly faster than the implant having
Formulation No. 1. Moreover, the implant having Formulation No. 2 represents a significant
improvement over Formulation No. 1 for reasons discussed below, particularly for intracameral
implants that tend to settle inferiorly into the anterior chamber angle of the eye.
Docket No. 19235 (AP) PATENT
Surprisingly, we found that by adjusting the proportions of the three biodegradable
polymers (R203S, RG752S, and R202H) present in our original three polymer drug delivery
system (Formulation 1), we could dramatically reduce the in vitro lifetime of the implant (Table
3) while maintaining the near linear rate of drug release over the approximate 60 day period we
had earlier observed for Formulation 1 (Figure 1). As shown in Table 3, an implant having
Formulation 2 degrades nearly twice as fast in vitro as an implant having Formulation 1.
Moreover, the moderate adjustment in polymer composition from Formulation 1 to Formulation
2 also improved the swelling behavior of the implant (Figures 2A and B). As shown in Figures
2A and B, the implant having Formulation 2 reaches a maximum swell diameter of about 550 to
600 µm and maximum length of about 1.5 mm approximately two months after placement in
PBS (pH 7.4, 37°C) and starts to contract thereafter, whereas the implant having Formulation 1
continues to swell even after two months, growing larger in both length and diameter over the
next 3 to 4 months that the measurements were taken. The differences in degradation rate and
swelling behavior for Formulation 1 and 2 implants are also visually evident in the microscope
images of these implants shown in Figure 3. We considered the low swell, rapid degradation
characteristics of Formulation 2 to be ideal for an intracameral implant that would ultimately
settle or be specifically placed in the anterior chamber angle of the eye of a patient with
glaucoma or ocular hypertension. Furthermore, the near linear, long term release of bimatoprost
observed for this implant in vitro, suggested that an extruded implant having Formulation 2
would be effective for lowering intraocular pressure in an eye for an extended period, perhaps as
long as two months or more, after placement in the anterior chamber of the eye.
In vitro drug release testing was performed by incubating the implants in 2 mL of
0.01M PBS pH 7.4 (1 implant per vial) in a shaking water bath set at 37°C and 50 rpm. A
sample was taken at 24 hours, and then every week for the first month, and then bi-weekly
thereafter. The release medium was replaced with fresh medium during each sampling time
point and the concentration of bimatoprost in the PBS was quantified using the HPLC. The
bimatoprost release profiles for implants having Formulation 1 and 2 (Table 1) are shown in
Figure 1. Data points represent the average release of 3 to 4 replicate implant samples.
Docket No. 19235 (AP) PATENT
In vitro polymer degradation testing was performed by incubating implants in 0.01 M
PBS pH 7.4 in a shaking water bath set at 37°C. For each formulation, 20 implants that were
each approximately 6 mm length were incubated in triplicates for a duration of 8 weeks.
Samples were taken weekly. The peak molecular weight (MW) was determined using a GPC
equipped with an R.I. detector and polystyrene as a standard. Degradation rate constants were
calculated from the 1 order kinetic curves to determine the in-vitro polymer degradation rate
constants for all formulations. The rank order of the formulations based on the total kinetic rate
constants and the estimated in-vitro life times (t ) for each implant formulation are
1000
summarized in Table 3. T represents the time at which the molecular weights of the polymers
1000
in the implant are expected to fall below 1000 Daltons.
For the implant swelling study (Figures 2A, 2B, and 3 and Table 3), each implant was
incubated in approximately 400 μL of PBS (pH 7.4, 0.01M) in Microwell 96-Well Assay Plates
and placed in a Shake N Bake Hybridization Oven set at 37°C and 50 rpm. Implant images were
recorded at 150X magnification at each time point and the lengths and diameters were measured
by Keyence Digital Microscope. Images were recorded at initialization, then weekly for the first
month, and biweekly thereafter.
An in vivo animal study in normal beagle dogs was conducted to evaluate the in vivo
efficacy, tolerability, and safety of the implants. Four formulations (Table 4) were evaluated in
dog groups 2, 3, 4, and 5. Group 1 received placebo implants. Each formulation was unilaterally
dosed (OD) as a single 20-μg (dosage) implant; four dogs per formulation; fellow eyes as
controls. IOP and Safety measurements were made weekly for 3 months, then bi-weekly up to 6
months. Efficacy was assessed by IOP and pupil diameter; tolerability by central corneal
endothelial cell density, and corneal thickness, and anterior chamber flare and cells; and safety
by ocular histology at 6 months. With regards to efficacy, all four formulations reduced IOP and
pupil diameter (dogs become miotic with bimatoprost exposure) (Figures 4 and 5). Reduction in
pupil diameter in dogs is an indication of bimatoprost exposure to the anterior chamber.
Insofar as the Implants described in Table 4, there were no differences between
treated and fellow eyes for the following tolerability measures: central corneal endothelial cell
density, central corneal thickness, nor anterior chamber flare and cells. The primary safety
Docket No. 19235 (AP) PATENT
measure was histology and there were no changes in structure of the ocular tissues that were
significant or adverse. These results with these implants (Table 4) show that single intracameral
doses of the new formulations using this invention demonstrate excellent efficacy, tolerability,
and safety.
A reduction in corneal endothelial cell density in the eye following injection of an
implant into the anterior chamber indicates the implant is injuring the corneal endothelium. This
occurs, for example, when the implant cannot fit within the anterior chamber angle because it is
too large, causing it to rest and rub against the corneal endothelium, or because, even if it does fit
within the angle, the implant swells to such an extent that it begins to contact and rub against the
corneal endothelium. Irritation of the corneal endothelium in this way eventually leads to a loss
of endothelial cell density at the focal center of the cornea, and possibly to focal opacity, corneal
edema, and corneal neovascularization.
Focal corneal endothelial cell density was measured in dogs 2, 5, 10, 16, and 26
weeks after intracameral injection of a 100-µg, 150-µg, 200-µg, or 250-µg (total weight) implant
prepared by an extrusion process and comprising Formulation 1. Treated animals (Groups 2-5)
received one implant in the anterior chamber of the right eye while the left eye was left
untreated. One group of dogs, Group 1, received no injection in either eye. As shown by Figure
6, by week 26 a reduction in corneal endothelial cell density was observed in the animals
receiving the 150-µg, 200-µg, and 250-µg implants. In contrast, there was no clinically
significant reduction in the corneal endothelial cell density in dogs that received the 100-µg
implant, which contained 20 µg of bimatoprost, as shown in Figure 6. These results show that the
size of the intracameral implant is an important consideration for the compatibility of the implant
with the anterior chamber of the eye, and to ensure the implant will fit within the anterior
chamber angle and cause no adverse effects such as edema or opacity long after placement in the
eye.
Docket No. 19235 (AP) PATENT
Table 1: Bimatoprost Containing Sustained Delivery Formulations (1-5) for the
production of extruded intracameral implants
Formulation Bimatoprost Polymer, excipient %w/w
No. %w/w R203S R202H RG752S RG858S PEG 3350
1 20 45 10 20 5
2 20 20 15 40 5
20 15 40 20 5
Table 2: Bimatoprost-containing Sustained Delivery Formulations (6-8) for the
production of extruded intracameral implants
Formulation Bimatoprost Polymer %w/w
No. %w/w
RG752S RG755S RG502 RG502H RG858S
3 20 35 15 15 15
4 20 40 5 5 30
6 20 20 50 5 5
7 20 25 50 5
8 20 30 20 30
Docket No. 19235 (AP) PATENT
Table 3: In vitro Properties of select intracameral implants produced by an extrusion
process
Implant Implant Duration of In vitro Implant swelling in
Formulation dimensions in vitro lifetime vitro (max) relative
(diameter x drug t1000 to initial size
length) and release (months)
total weight
1 250 µm x 2.3 mm Diameter: 2.7–3.0 X
~60 Days 9-11
150 µg Length: 1.2X
2 250 µm x 2.3 mm Diameter: 2.7–3.0 X
~60 Days 4-6
150 µg Length: 1.2X
250 µm x 2.3 mm Diameter: 2.7–3.0 X
~60 Days 4-6
150 µg Length: 1.0X
3 250 µm x 2.3 mm Diameter: >4X
~60 Days 3-4
150 µg Length: <0.5X
4 250 µm x 2.3 mm Diameter: >4X
~60 Days 3-4
150 µg Length: <0.5X
Table 4: Bimatoprost-containing extruded intracameral implants used for in vivo study
in dogs
Dog Formulation Bimatoprost Implant Implant Total Implant
Group No. Dose (µg) Morphology Dimensions Weight (µg)
(shape) (mm)
1 Placebo: 0 Rod Diameter: ~98.2
62.5% RG755S, ~0.257
% RG 752S, Length: ~1.43
6.25% RG502H,
6.25% 502S
2 2 20 Rod Diameter: ~103
~0.252
Length: ~1.61
3 6 20 Rod Diameter: ~99.8
~0.256
Length: ~1.51
4 7 20 Rod Diameter: ~101.6
~0.248
Length: ~1.50
8 20 Rod Diameter: ~99.1
~0.249
Length: ~1.59
Docket No. 19235 (AP) PATENT
Claims (22)
1. A biodegradable intraocular implant for reducing intraocular pressure (IOP) in an eye, the implant comprising a biodegradable polymer matrix, polyethylene glycol 3350, and a prostamide as the active agent, wherein the prostamide and polyethylene glycol 3350 are associated with the biodegradable polymer matrix, which comprises a) an ester end poly(D,L-lactide) having an inherent viscosity of 0.25-0.35 dl/g, b) an acid end poly(D,L-lactide) having an inherent viscosity of 0.16-0.24 dl/g, and c) an ester end poly(D,L-lactide-co-glycolide) having an inherent viscosity of 0.16- 0.24 dl/g and a D,L-lactide to glycolide molar ratio of about 75:25; wherein the prostamide constitutes 18 to 22% of the implant by weight, the ester end poly(D,L-lactide) constitutes 18 to 22% of the implant by weight, the acid end poly(D,L- lactide) constitutes 13.5 to 16.5% of the implant by weight, the ester end poly(D,L-lactide- co-glycolide) constitutes 36 to 44% of the implant by weight, and wherein the polyethylene glycol 3350 constitutes 3.5 to 6.5% of the implant by weight, wherein the inherent viscosity of each of the poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers is determined for a 0.1% solution of the polymer in chloroform at 25°C.
2. A biodegradable intraocular implant according to claim 1, wherein the prostamide constitutes 20% of the implant by weight, the ester end poly(D,L-lactide) constitutes 20% of the implant by weight, the acid end poly(D,L-lactide) constitutes 15% of the implant by weight, the ester end poly(D,L-lactide-co-glycolide) constitutes 40% of the implant by weight, and wherein the polyethylene glycol 3350 constitutes 5% of the implant by weight.
3. The implant of claim 1 or claim 2, wherein the implant is rod-shaped and is formed by a hot-melt extrusion process and wherein the implant is 150 µm to 300 µm in diameter or width, 0.50 mm to 2.5 mm in length, and 30 µg to 100 µg in total weight. Docket No. 19235 (AP) PATENT
4. The implant of any one of claims 1-3, wherein the implant does not contact the corneal endothelium after placement in the anterior chamber of an eye.
5. The implant of any one of claims 1-4, wherein the implant is effective for reducing intraocular pressure in an eye for 2 months or longer after placement in the eye.
6. The implant of any one of claims 1-5, wherein the prostamide is a compound having the formula (I) wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A is an alkylene or alkenylene radical having from two to six carbon atoms, which radical may be interrupted by one or more oxide radicals and substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups wherein said alkyl radical comprises from one to six carbon atoms; B is a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals having from four to ten carbon atoms wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms; X is –N(R ) wherein R is independently selected from the group consisting of hydrogen and a lower alkyl radical 1 2 6 having from one to six carbon atoms; Z is =O; one of R and R is =O, –OH or a –O(CO)R 6 1 2 6 group, and the other one is -OH or -O(CO)R , or R is =O and R is H, wherein R is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or -(CH )mR wherein m is 0 or an integer of from 1 to 10, and R is cycloalkyl radical, having from three to seven carbon atoms, or a hydrocarbyl aryl or heteroaryl radical, as defined above. Docket No. 19235 (AP) PATENT
7. The implant of any one of claims 1-5, wherein the prostamide is bimatoprost.
8. A use of a biodegradable polymer matrix, polyethylene glycol 3350, and a prostamide as the active agent, in the manufacture of an intraocular implant for reducing ocular pressure in an eye of a mammal in need thereof, wherein the intraocular implant is as defined in claim 1 or claim 2.
9. The use of claim 8, wherein the mammal is a human patient that has elevated intraocular pressure, ocular hypertension, or glaucoma.
10. The use of claim 8 or claim 9, wherein the implant is to be placed in the anterior chamber of an eye of the patient.
11. The use of any one of claims 8-10, wherein the implant is effective for reducing intraocular pressure in the eye for at least two months after placement in the anterior chamber of the eye.
12. The use of any one of claims 8-11, wherein the prostamide is bimatoprost.
13. The use of any one of claims 8-12, wherein the implant is formed by an extrusion process and wherein the implant is 150 to 300 µm in diameter or width, 0.50 to 2.5 mm in length, and 30 to 100 µg in total weight.
14. The use of any one of claims 8-13, wherein the implant does not contact the corneal endothelium after placement in the anterior chamber of the eye.
15. The use of any one of claims 8-14, wherein the implant is to be placed in the eye(s) using an intraocular delivery apparatus, the apparatus comprising an elongate housing and a cannula extending longitudinally from the housing, the cannula having a proximal end and a distal sharp end and having a lumen extending therethrough, the lumen having an inner Docket No. 19235 (AP) PATENT diameter sufficient to receive the implant and permit translation of the implant through the lumen and into the eye of the patient.
16. An apparatus for delivering a biodegradable intraocular implant into the eye of a patient, the apparatus comprising an intraocular implant according to claim 1, an elongate housing and a cannula extending longitudinally from the housing, the cannula having a proximal end, a distal sharp end, and a lumen extending therethrough, the lumen having an inner diameter sufficient to receive the intraocular implant and permit translation of the implant through the lumen and into the eye of the patient.
17. The apparatus of claim 16, wherein the cannula is a 25 gauge, 26 gauge, 27 gauge, 28 gauge, 29 gauge, or 30 gauge needle.
18. A method for making a biodegradable intraocular implant according to claim 1, the method comprising mixing the prostamide with the poly(D,L-lactide) and poly(D,L-lactide-co- glycolide) polymers and polyethylene glycol 3350, extruding the mixture to form a filament, followed by cutting the filament to length suitable for placement in the anterior chamber or vitreous body of an eye to thereby form an intraocular implant.
19. An implant as claimed in any one of claims 1-7 substantially as herein described and with reference to any example thereof.
20. A use as claimed in any one of claims 8-15 substantially as herein described and with reference to any example thereof.
21. An apparatus as claimed in claim 16 or 17 substantially as herein described and with reference to any example thereof.
22. A method as claimed in claim 18 substantially as herein described and with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361898241P | 2013-10-31 | 2013-10-31 | |
US61/898,241 | 2013-10-31 | ||
PCT/US2014/063569 WO2015066548A1 (en) | 2013-10-31 | 2014-10-31 | Prostamide-containing intraocular implants and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ718992A NZ718992A (en) | 2021-11-26 |
NZ718992B2 true NZ718992B2 (en) | 2022-03-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020201778B2 (en) | Prostamide-containing intraocular implants and methods of use thereof | |
DK3205333T3 (en) | REDUCTION OF INTRAOCULAR PRESSURE WITH INTRACAMERAL PROSTAMID IMPLANTS | |
US20240225893A9 (en) | Sustained-release implants for lowering intraocular pressure with extended duration of effect | |
NZ718992B2 (en) | Prostamide-containing intraocular implants and methods of use thereof |